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1 The Guillain-Barre syndrome: an introduction 
1.1 Introduction 
The Guillain-Barre syndrome (GBS) is an acute immune-mediated disorder of the peripheral 
nerves. The essential features are a rapidly progressive, more or less symmetrical weakness 
of the limbs and decreased or absent tendon reflexes. The weakness reaches its nadir 
(maximum severity) by definition within four weeks, but it is usually seen within two weeks. 
In 20-30% of the patients, weakness is so severe that artificial ventilation is needed. 
People of all age, gender or race can be affected by this polyneuropathy. The first symptoms 
of GBS are often preceded by an infection. Seventy percent of the patients report influenza-
like symptoms, a respiratory infection or a gastro-enteritis within the three weeks prior to 
the onset of the disease. 
The first description of what is now called the Guillain-Barre syndrome, was given by 
J.B.O. Landry in 1859 1. The summation of clinical characteristics was extended by typical 
findings in the cerebrospinal fluid as described by G. Guillain, JA Barre and A Strohl in 
1916 2• As research progressed, many studies reported on the clinical diversity of GBS. As 
a consequence, the concept of GBS shifted from a single clinical entity to a disease with 
heterogeneity in presentation, course and outcome. 
Nowadays GBS is considered to be a post-infectious immune-mediated acute polyneuro-
pathy with a heterogeneous symptomatology. 
1.2 Diagnosis 
UGuillain-Barre syndrome is a recognisable entity for which the basis for diagnosis is 
descriptive in our present state of knowledge. The features, which allow a diagnosis, 
include clinical, laboratory, and electrodiagnostic criteria. The problem is not with 
recognition of a typical case, but with knowing the boundaries by which the core 
disorder is delimited. The following criteria are established, in light of current know-
ledge and opinion, to define those limitsu. This is how the first diagnostic criteria for 
GBS were introduced in 1978 by an ad hoc National Institute of Neurological Disorders 
and Stroke (NINCDS) committee 3. Motivation for the set up of these criteria was the 
increasing incidence of GBS in association with the swine-flu vaccine campaign in 1976. 
As research progressed and knowledge was expanded, the criteria were revised in 1990 
(table 1) 4 Originally, these criteria were set up to facilitate epidemiological research. In 
practice it seems appropriate to define GBS clinically, according to the simple diagnostic 
criteria and subsequently add further characteristics. This may result in subgroups within 
the broad clinical definition. Depending on the time-course, the pattern of weakness and 
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the presence of sensory symptoms, different diagnoses have to be considered. 
Table 1 Diagnostic criteria 
Guillain-Barre syndrome 
Features Required for the Diagnosis 
• Progressive motor weakness of more than one limb. 
• Areflexia or marked hyporeflexia in very weak muscles (<grade 3 MRC). 
Features Strongly Supportive of the Diagnosis 
• Progression over days to a maximum of four weeks. 
• Relative symmetry. 
• Mild sensory signs or symptoms. 
• Cranial nerve involvement. 
• Onset of recovery 2-4 weeks after progression stops. 
• Autonomic dysfunction. 
• Initial absence of fever. 
• Elevated CSF protein after the first week of symptoms. 
• CSF cell counts of 1 0 or fewer mononuclear leukocytes/mm3 . 
• Abnormal electrodiagnostics with conduction slowing or block. 
• No other identifiable cause. 
Features That Rule out the Diagnosis 
• A current history of hexacarbon use. 
• Abnormal porphyrin metabolism. 
• A history or finding of recent diphtheric infection. 
• Lead intoxication. 
• The occurrence of a purely sensory syndrome. 
• Diagnosis of poliomyelitis, botulism, hysterical paralysis or toxic neuropathy. 
Adapted from the revised version of the diagnostic criteria for GBS, set up by the 
National Institute of Neurological Disorders and Stroke 4 
pagina 4 
1 The Guiilain-Barre syndrome: an introduction 
1.3 Pathogenesis 
The clinical picture of polyneuropathy in GBS is the result of damage to the myelin sheet 
and/or axon. This damage appears to be the result of an aberrant immune response to an 
infectious agent. The role of the immune system in the development of GBS originates, 
among others, from the fact that 70% of the GBS patients reports a preceding infection 
prior to the onset of symptoms. Furthermore, the course of the disease can be influenced 
by immune-modulating therapies as plasmapheresis {PE) and intravenous immunoglobulins 
(IVIg). Finally, with the finding of antibodies directed against structures in the peripheral 
nerve, the role of the immune system seems indisputable. 
In most cases the nerve damage is primarily caused by demyelination. Pathophysiological 
studies show lymphocytic infiltrates in spinal roots and peripheral nerves, followed by 
macrophage-mediated segmental stripping of the myelin 5. As a consequence electrical 
nerve impulses are disrupted leading to slowing of nerve conduction and in some cases to 
conduction block 6• In some cases, mostly severely affected patients, the inflammatory 
demyelination is accompanied by destruction and loss of axons 7-9. It is difficult to distinguish 
these cases from the primary axonal forms in which the primary immune attack is directed 
against the nerve axons 10. 12 . In these cases macrophages penetrate the basal lamina of 
the Schwann cell resulting in destruction of the axons. This process is without significant 
demyelination and lymfocytic infiltrates are scarcely present 10. The clinical phenotype of 
the primary axonal form and primary demyelinating form followed by secondary axonal 
degeneration is similar. Since pathological material from GBS patients is scarce and 
electrophysiological techniques are not able to discriminate between primary or secondary 
axonal degeneration, the discrimination between these two groups is generally not possible 
in daily practise. 
It is not exactly known when and how nerve tissue becomes involved in the immune res-
ponse and this has been a major subject of GBS research over the last years. At present 
the theory of "molecular mimicry" draws the attention and up to now it appears to be the 
most attractive hypothesis in the development of GBS. As reaction to the presence of a 
microbial agent, antibodies and/or T cells are produced to act directly against the microbial 
antigens. Due to the structural resemblance of the antigens and host tissue, the antibodies 
and/or T cells not only destruct the pathogen but also cause damage to the host tissue "-
In GBS, the most extensively described relation between a pathogen, host tissue and anti-
bodies is the relation between a preceding infection with Campylobacter jejuni (C.jejum) 
and the presence of serum anti-ganglioside antibodies cross-reacting with lipopolysac-
charides from C.jejuni 13-16 . Gangliosides are a subgroup of membrane glycolipids present 
in the nervous system. Different types of gangliosides are described. The composition of 
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gangliosides in axons or myelin, but also in motor and sensory nerves and in ventral and 
dorsal nerve roots, varies 13 . As will be described below, the difference in presence and 
type of ganglioside are related to the presence of certain clinical subgroups in GBS. 
Not all infections with C.jejuni or other pathogens result in the development of GBS. 
Furthermore, anti-ganglioside antibodies are not exclusively found in patients with GBS. 
From this, it follows that other components are necessary to induce the development of 
GBS. Most likely hostfactors play a role resulting in a susceptibility to develop GBS. The 
latter may be genetically determined or dependent on the immune status of an individual. 
The fact that there is no straightforward genetic component responsible for the development 
of GBS in general is supported by the lack of familial clustering and the lack of convincing 
associations with any of the HLA classes 17-21 . A promising start is made to investigate the 
role of polymorph.lsms in certain immune response genes in the development of GBS 20;22'23 . 
Cross-reacting antibodies Figure 1 
Molecular Mimicry in GBS 
1.4 Subgroups 
As mentioned, GBS is considered to be a heterogeneous disorder. Because the pathophysio-
logical mechanism has not been fully elucidated it is not known what the exact contribution 
is of preceding infections and the presence of anti-ganglioside antibodies. Recent studies 
reporting on the relation with certain immune-response gene polymorphisms have revitalised 
the thought that hostfactors are likely to play a role 24 . It is not known if subgroups are 
completely based on similar underlying pathophysiologic mechanisms and consequently, 
the diversity of the clinical picture of GBS is fully determined by the preceding infection, 
presence of anti-ganglioside antibodies and/or hostfactors. Another possibility is that 
different mechanisms play a role, which result in a similar clinical picture. 
Classification of the subgroups is possible on different levels of the disease and characte-
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ristics on several levels of the disease can be found in one subgroup (table 2 and figure 2). 
The most common subgroup in the western world is the sensory-motor variant. It is the 
classical descending paralysis with both involvement of the motor and sensory fibres. This 
probably most resembles the Guillain-Barre syndrome as described by G. Guillain, J.A. 
Barre and A. Strohl in 1916 2 . On the level of electrophysiology and pathophysiology, the 
sensory-motor variant can be termed as acute inflammatory demyelinating polyneuropathy 
(AIDP). As mentioned earlier, this subgroup is characterised by primary demyelination, 
sometimes accompanied by axonal loss. With respect to the preceding infections and 
related anti-ganglioside antibodies, this variant has been associated with the 
Cy1omegalovirus (CMV) and the presence of anti-GM2 antibodies 25-2'- Patients with a pre-
ceding CMV infection are characterised by a younger age, a relatively severe course with 
a high frequency of respiratory insufficiency, often cranial nerve involvement and severe 
sensory loss 25 . 
The pure motor form accounts for 10-20% of the cases. It is, beside the absence of sen-
sory deficits, characterised by a rapid onset of weakness, initially predominant distal 
weakness, an earlier nadir and sparing of the cranial nerves 30 . In the pure motor type, a 
preceding infection with C.jejuni is frequently described together with the presence of 
anti-GM1, anti-GM1 b and anti-GaiNAc-GD1 a antibodies 30-33 . This pure motor form is also 
described in Japan and China and, based on electrophysiological and pathophysiological 
findings, called "AMAN" (acute motor axonal neuropathy) 34-36 Here again, a preceding 
infection with Cjejuni is frequently described together with the presence of anti-GM1 36:37 . 
Besides the AMAN variant also patients with severe sensory-motor symptoms were des-
cribed in China, termed "AMSAN" (acute motor-sensory axonal neuropathy). Based on 
pathological findings, the authors suggested that "AMSAN" could be a more severe form 
of "AMAN" 35. Because pathology is scarce and electrophysiological techniques are not 
able to discriminate between primary or secondary axonal degeneration, the terms 
"AMAN" and "AMSAN" are not frequently used 7'38-41 . 
In other variants of GBS cranial nerve dysfunction is the most prominent feature. The most 
frequently reported subtype is the Miller Fisher syndrome (MFS). This syndrome, characte-
rised by ophtalmoplegia, ataxia and absence of the tendon reflexes, occurs in 5% of all 
GBS cases 42 . In MFS, the respiratory muscles are seldom affected and the disease appe-
ars to run a relatively mild course. A preceding infection with Cjejuni is also frequently 
reported in MFS and anti-GQ1 b antibodies are almost always present 43;44 . 
In case of the pharyngo-cervico-brachial (PCB) variant, difficulty in speech and swallowing 
is most prominent. In PCB, the facial nerve is often affected and there is progressive 
weakness in the oropharyngeal muscles, the neck, shoulders and proximal arm muscles 
45
-
48
. Mild weakness of the limbs and reduced tendon reflexes do not exclude the diagnosis 
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of PCB. Associations have been described between PCB and antibodies against GT1 a 
and GM1b 48•51 • 
In a study concerning these cranial variants, significant overlap was found between the 
variants and the classical GBS. In 59% of the cases, where symptoms started in the ocu-
lomotor region, difficulty in swallowing followed, indicating involvement of the lower cranial 
nerves. In 33% of the cases, where symptoms started in the lower cranial nerve region, 
the oculomotor nerves became ·Involved. In both variants, about half of the patients devel-
oped a descending weakness in the extremities 52 . 
Table 2 Guillain-Barre syndrome, patterns within the clinical concept. 
I GBS I 
I I I I I 
I Sensory Motor I I MFS I 1 I PCB I Pure Motor I 
Demyelinating Axonal 2 Demyelinating! Axonal (AIDP) (AM SAN) (AMON) (AM SAN) 
I 
""" 
I 
CMVI I C.jejuni I 3 ] C.jejuni~ 
I I ~ 
GM21 
I 
GQ1b I 4 
I 
GT1a, II GM1b, IGM1 GM1b GaiNAc-GD1a 
MFS Miller Fisher syndrome 1 Clinical subgroups 
PCB Pharyngo-Cerv·lco-Brachial variant 2 Electrophysiological/ 
AIDP Acute Inflammatory Demyelinating Pathophysiological 
Polyneuropathy 3 Infections 
AM SAN Acute Motor-Sensory Axonal Neuropathy 4 Anti-ganglioside antibodies 
AMON Acute Motor Demyelinating Neuropathy 
AMAN Acute Motor Axonal Neuropathy 
CMV Cytomegalovirus 
C.jejuni Campylobacter Jejuni 
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Figure 2 Association between clinical subgroups, infections and anti-
ganglioside antibodies Axonale 
1.5 Treatment 
Supportive treatment 
Although at present specific treatment is available, general care is still of utmost importance 
for the GBS patient. Because of the risk of autonomous dysfunction and the unpredictable 
course of the disease, the patient should be carefully monitored from the beginning. In doing 
so, one should especially be aware of the possibility of respiratory distress, aspiration and 
autonomic dysfunction. The latter expresses itself as wide fluctuations of pulse or blood 
pressure, cardiac arrest or ileus. Pain often is a great burden to the patient. Although special 
mattresses and frequent repositioning may be helpful, even the use of epidural morphine 
application has been advocated 53 . 
Specific treatment 
Table 3 gives an overview of all randomised controlled clinical trials (RCT) and two pilot 
studies pertormed in GBS patients. In most of these studies, only patients were included 
who were within 2 weeks after onset of symptoms and unable to walk independently. 
Outcome measurements were mostly based on the Hughes' disability scale. Table 4 
shows this scale which assesses a disability score (!-score) of patients mainly based on 
mobility 54 The first RCT was performed in 1978 54 Unfortunately, it could not show the 
benefit of low dose prednisone as sole treatment In 1993, a RCT was conducted to 
investigate the efficacy of high dose prednisone on improvement in GBS patients 55 . Again 
no positive effect was found at 4 weeks. 
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The efficacy of PE was the first to be demonstrated in two large clinical trials 56;57 . In both 
studies, improvement started earlier and artificial respiration was significantly less fre-
quently indicated in patients treated with PE compared to patients who received only sup-
portive treatment. In the above described RCTs, only severely affected patients were inclu-
ded, i.e. patients unable to walk independently. In 1997, a paper was published on the 
beneficial effect of PE, also in patients who were only mildly affected 58 
The positive results of PE treatment reflected not only considerable decrease of morbidity, but 
also a considerable degree of economic savings. However, drawbacks of PE treatment were 
its contraindications, the invasive character and treatment failures during administration. 
Based on the positive results of IVIg treatment of patients with chronic inflammatory 
demyelinating polyneuropathy (CIDP) and other autoimmune mediated diseases, a RCT 
was conducted aiming for equal efficacy of IVIg and PE in GBS patients 59 If IVIg and PE 
would prove to be equally efficient, IVIg would be preferable since it is widely available and 
easy to administer. In the Netherlands, 150 GBS patients were included. This study showed 
that IVlg was at least as effective as PE in terms of improvement in mobility at 4 weeks. 
Subsequently, an international study has been published including 383 patients 60 
Besides confirmation of the positive effect of IVIg, this RCT investigated the effect of treat-
ment with PE followed by treatment with lVI g. The equal effect of IVIg and PE could be 
confirmed. However, no significant additional effect was found of the combined treatment. 
Based upon the above described results, IVIg can now be regarded as an effective treat-
ment for patients with GBS and is generally preferable. 
Although IVIg improves outcome, morbidity is still considerable. Therefore, the need 
remains to investigate alternative or additional therapy for GBS patients. This has led to 
the conduction of a pilot study on the additional effect of methylprednisolone (MP) on 
standard IVIg treatment 61 . The positive results of this study were the base for the RCT on 
the additional effect of MP described in this thesis. 
Table 4 The Hughes' disability scale 
F-score •· 
0 Health 
1 Minor siqns or symptoms of neuropathy but capable of runninq 
2 Able to walk without support or a stick but incapable of runninq 
3 Able to walk with a stick, appliance, or support 
4 Confined to bed or chairbound 
5 Requirinq artificial ventilation 
6 Dead 
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1.6 Prognosis 
The retrospective epidemiological survey described in this thesis shows that in about 28% of 
the patients, the disease runs a relatively mild course and these patients remain ambulant 
during the course of the disease 62 . In the other patients the disease progresses and finally, 
artificial ventilation is necessary in 20 to 30% of these patients 42;59;63 . After a period of 
progression a plateau phase follows which may take several weeks or months. 
Subsequently recovery starts. Without specific therapy, the median time towards independent 
walking takes about 85 days for patients not able to walk independently 63 . Randomised trials 
on the effect of PE and IVIg showed a median time towards walking between 49 and 70 days 
ss;s?;s9;60 .The reported mortality rates range from 2 to 12% 56"60:64-66 . The lower rates are mainly 
derived from treatment trials where patients with serious co-morbidity are excluded. 
De Jager and Minderhoud studied long term outcome in 57 patients. With a follow-up time 
varying between 2 and 24 years, they found that 35% of the patients was fully recovered, 
in 35% of the patients a mild handicap was left and 30% of the patients suffered from a 
severe handicap 67 . Fletcher et al. studied long-term outcome in 60 GBS patients requiring 
mechanical ventilation. The mortality appeared to be 20%. However, 79% of the survivors 
eventually regained independent ambulation 68 . 
Outcome may be predicted in an early stage of disease using prognostic indicators, 
identified in a variety of studies. Most stud"1es show that older age, need for ventilatory 
support, a rapidly progressive course and low compound muscle action potentials after 
distal nerve stimulation (EMG) are predictors of poor outcome 63'64'68' 73 In the Dutch IVIg 
GBS trial, a multivariate analysis on the collected data of 147 GBS patients was performed 
in order to study prognostic factors 74 . The importance of older age, a rapid onset and 
severity of weakness were confirmed. The most powerful predictor in this study was, 
however, an antecedent episode of diarrhoea. Rees et al. also found that a preceding 
infection with C.jejuni, the commonest recognised cause of diarrhoea, was an important 
prognostic factor 75 . The Italian Guillain-Barre study group again reported an antecedent 
gastro-enteritis as a predictor of worse outcome even as the Plasma Exchange/-
Sandoglobulin GBS Trial Group 66'"- Interestingly, in the Dutch trial, diarrhoea was only an 
important prognostic factor in the patients treated with PE and not in patients treated with 
IVIg 31;74. 
In conclusion the prognosis of GBS varies from complete recovery to death depending on 
prognostic factors and applied therapy. Frequently described predictors of poor outcome 
are older age and severe neurological damage at nadir (expressed by the need of artificial 
ventilation). Factors associated with a mild course of GBS are not known and are being 
studied as part of this thesis. 
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1.7 Outline of this thesis 
This thesis focuses on the heterogeneity of GBS. Because the pathophysiological mechanism 
has not been fully elucidated. it is only partially known what causes this heterogeneity and 
determines the differentiation into specific subgroups. 
Besides a contribution to the unravelling of the pathophysiological mechanism, description 
and recognition of the subgroups is important because the prognosis and response to 
therapy may differ. 
The first part of this thesis describes the epidemiology of GBS (Chapter 2). Epidemiology 
can provide clues on the etiology by studying the disease at different time periods. at dif-
ferent places and among different types of people. Paragraph 2.1 describes a review on 
the literature regarding the worldwide epidemiology of GBS. Paragraph 2.2 describes an 
epidemiological survey in the Southwest Netherlands. This survey comprises 476 patients 
and provides an overall incidence rate (IR) for GBS in the Netherlands together with IR for 
age, gender and seasons. Paragraph 2.3 describes the results of a study on the increasing 
number of GBS cases observed on the Dutch Antilles island Curagao. IR and clinical 
characteristics of the patients are assessed and compared with the results of the Dutch 
survey on GBS. 
The second part of this thesis describes studies on clinical aspects of GBS {Chapter 3). 
In the first two paragraphs the clinical subgroup of mild patients is described. Paragraph 
3.1 describes a retrospective study and provides data on clinical characteristics and pre-
ceding infections in mildly affected patients. Paragraph 3.2 describes a prospective study on 
mild patients. Here, the focus is on the differences in the time course of the disease compa-
red to the severely affected patients. It includes an analysis of serological proven preceding 
infections and the presence of anti-ganglioside antibodies. Furthermore, the outcome in 
mild patients is described and the need to treat this group of patients is discussed. 
Paragraph 3.3 describes the course of the disease and outcome of a clinical subgroup of 
GBS, the Miller Fisher syndrome patients. In Chapter 4 firstly. the results of a double 
blind placebo controlled randomised trial on the additional effect of methylprednisolone on 
standard treatment with IVIg is described. In paragraph 4.2 the effect of publication of the 
positive effect of intravenous immunoglobulin therapy in GBS patients on the referral pat-
tern is described. In Chapter 5, the genera! discussion, the main results are discussed 
and conclusions together with suggestions for future studies are given. 
Chapter 6 is a summary in English and in Dutch. 
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Epidemiology of the Guillain-
Barre syndrome 
Chapter 2 
2.1 Epidemiology of the Guillain-Barre syndrome: a review 
Incidence rates 
GBS can affect all people and is not restricted to specific areas nor related to factors as 
gender, age, race, standard of living or climate. Over the years 29 studies were assessed on 
the epidemiology of GBS (table 1). The reported crude incidence rates (IR) vary from 0.16 to 
2.2 cases per 100.000 persons per year. When evaluating epidemiological data based on 
population surveys it is important to consider 1) the method of case ascertainment. 2) the 
time period under investigation and 3) the size of the population. The most commonly 
used method of case ascertainment is the use of the NINCDS criteria for GBS 1• When 
restricting to the studies that used these criteria, to a time period ?.7 years (median number 
of years under investigation) and to studies including ~54 patients (median number of 
patients under investigation). the IR varies from 0.83-1.49/100.000. The studies were per-
formed between 1935 and 1997 and there appears to be no change in IR over the years. 
Although GBS affects people from all ages. a clear increase in incidence with age has 
been reported in most studies 2-6. Besides the increase in lR with age, some studies show 
a peak around 20-30 years (a bimodal age distribution) 7-10 
In general, men are more frequently affected than women. In only four studies this diffe-
rence reached statistical significance 2;5;6;11 . 
Two third of the GBS patients notice an infection approximately one to three weeks before 
the onset of weakness. Although some of these infections tend to show a seasonal pre-
ponderance, there is hardly ever a significant difference between seasons reported in the 
occurrence of GBS. From the studies reporting on the seasonal occurrence of GBS, there 
appears to be a slight lean towards autumn and early winter 2 ;4;6;12-14· 
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Antecedent factors 
Many factors preceding GBS have been described with the suggestion that they play a 
role in the aetiology of the disease. Convincing are the associations with certain viruses 
and bacteria 15;16 . Also extensively described is the relationship with specific vaccines or 
drugs but most observations are, however, anecdotal 17-22 • Little doubt is left about the 
relationship of GBS with the swine-flu vaccination in 1976 and the use of the antidepressive 
drug, Zimeldine 18;19 . Finally, cases have been outlined where GBS followed pregnancy, 
surgery and malignancies 23-25 . Here again, no cause-and-effect relationship has been 
established so far. In conclusion, the relation between certain bacteria and viruses and the 
occurrence of GBS is generally accepted. The relation with factors as drugs, vaccines, 
pregnancy and malignancy however, are anecdotal and subject of discussion. 
Campylobacter jejuni (Cjejuni), cytomegalovirus (CMV), Epstein-Barr virus (EBV) and 
Mycoplasma pneumonia are micro-organisms most frequently reported as preceding 
agent"·''- Recently, most attention has been drawn by Cjejuni. In 1984, Kaldor and 
Speed reported a preceding infection with this Gram-negative flagellated rod in 38% of 
their GBS patients 26 . This relationship has been confirmed extensively and much effort 
has been made to further investigate this association 15;27;30-34 . This has led to the definition 
of a Cjejuni-related subgroup which is associated with a pure motor form, a more severe 
clinical course and anti-GM1 antibodies 15;35;36. Similarly, an association has been 
demonstrated between a preceding CMV infection, a more severe course of the disease 
and anti-GM2 antibodies 28;37 . 
If preceding factors would be the only etiologic factor in GBS, one should expect outbreaks 
of GBS on a regular base. Although not regular, some outbreaks have been described. 
The most extensively studied outbreak is the one associated with the swine-flu vaccine in 
1976 and will be discussed in more detail below. Also in 1976, a 300 times the expected 
IR was found in Jordan 38 . A few weeks after a community-wide waterborne outbreak of 
acute diarrhoea, 16 cases of GBS were found within one month. In the light of the current 
knowledge of Cjejuni as frequent preceding infection, it is well possible that this agent 
was responsible for this outbreak. In 1968 in Colombia, 17 cases were identified within 
two months but no clear common factor could be found 39 . 
The swine-flu vaccine 
In the fall of 1976, over 35 million inhabitants of the United States received a vaccine 
containing the A/New Jersey swine influenza virus. Two months later a marked increase 
of GBS was reported among receivers of the vaccine and the vaccination program was 
suspended. A nation wide surveillance was set up by the Centers for Disease Control 
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and Prevention (CDC). They established an attributable risk of vaccine-related GBS in the 
adult population of just under one case per 100.000 vaccinations 19. The validity of this 
study was heavily criticised because it was performed in a crisis atmosphere and lacked 
diagnostic guidelines 40. A commission was ordered to re-evaluate the cases and it was 
finally concluded that there was a relative risk of 4-8 times for GBS in the first six weeks 
after vaccination 41 . What really caused this increase has never been fully understood. 
Some findings make it even more disputable whether there has really been an increase in 
incidence. First, earlier vaccination programs, some including vaccination against the 
swine-flu, were never associated with an increase in incidence. Second, nation wide sur-
veys in the years after 1976 did not show a relation between the influenza vaccine and 
GBS 42 -44 . Third, US Army personnel was yearly vaccinated with a swine-flu vaccine and 
no increase in the number of GBS cases was found 45 . If there indeed was an increase in 
GBS cases due to the vaccine, it seems to be uniquely related to that particular type of 
swine-flu vaccine. 
The Chinese paralytic syndrome 
A unique epidemiological phenomenum concerning GBS is the so-called "Chinese paraly-
tic syndrome". This variant of GBS has been recognised for at least 20 years in Northern 
China. McKhann et al. described a group of 3200 patients with remarkable epidemiological 
features. This group mainly consists of children in rural areas who are predominantly affected 
during late summer. Most of these patients suffered from the subtype 'acute motor axonal 
neuropathy' (AMAN) which is electrophysiologically and pathologically characterised by 
motor axonal degeneration with minimal cellular inflammation 46;47 . A prospective study 
showed a significantly higher percentage of serologically proven C.jejuni infections in the 
AMAN patients compared to healthy controls 48 . 
In conclusion, GBS can affect people worldwide, regardless of age, gender or race. In 
the literature, IR are reported between 0.83 to 1.49/100.000. Men and older patients are 
more frequently affected. Two third of the GBS patients experience an infection in the 
weeks prior to the first symptoms. A preceding infection with C.jejuni is most frequently 
reported. 
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le 1 Reported Incidence rates of Guillain-Barre Syndrome 
Study Population 
Uusimaa County, 
Southern Finland 59 
I Ointar·iio and Quebec, 
Canada 61 Ontario 
Period of Study 
1983-1989 1302 2.07 2.02 No 
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2.2 Epidemiology of the Guillain-Barre syndrome in the 
Southwest Netherlands 
Based on the article "Mild forms of Guillain-Barre syndrome in an epidemiological survey 
in the Netherlands". van Koningsveld R., MD, Van Doorn P.A., MD, PhD, Schmitz P.I.M., 
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Abstract 
Objective: Assessment of incidence rates of the Guillain-Barre syndrome (GBS) in the 
Netherlands over a ten-year period. Investigation of a relationship between possible sea-
sonability in GBS and the occurrence of preceding infections. 
Methods: Records of GBS patients admitted between 1987 and 1996 from all 45 hospitals 
in the Southwest of the Netherlands were evaluated covering a population of 4.2 million 
inhabitants. 
Results: 476 patients met the NINCDS-criteria for GBS. This resulted in a crude incidence 
rate (IR) of 1.18/100.000 inhabitants. This IR increased linearly with age (p<0.01). Men 
were more frequently affected than women (p<0.01). No seasonal preponderance for GBS 
was found, nor for any of the preceding infections. 
Conclusion: Overall IR in the Netherlands are similar to those found in other studies. The 
incidence increases linearly with age and men are more frequently affected than women. 
There appears to be no relationship between the seasonal occurrence of preceding infections 
and the incidence of GBS within the year. 
Introduction 
Epidemiological knowledge of the Guillain-Barre syndrome (GBS) is limited with respect to 
recent findings regarding preceding infections, prognostic factors and treatment options. 
Overall, 15 studies on GBS using the National Institute of Neurological Disorders and 
Stroke criteria (NINCDS) have shown incidence rates (IR) between 0.8 and 2.0 per 100.000 
inhabitants 1-1 5. Some of the more recent studies have also reported on the epidemiology 
of preceding infections 4 ,6·12 . 
Here, we report an epidemiological study, retrospectively performed over a period of ten 
years in the Southwest of the Netherlands. We assessed the IR of GBS in the Netherlands 
and its fluctuations over a period of 10 years. Furthermore, we hypothesised a relationship 
between seasonal distribution of GBS and preceding infections. It has been suggested 
that the failure to find a seasonal preponderance of GBS is due to the fact that there is an 
opposite seasonal occurrence between the most frequent antecedent events 16 . 
Material and Methods 
The area and time-period 
The survey was carried out in the Southwest of the Netherlands; an area comprising 4.2 
million inhabitants which is about 25% of the population of the Netherlands. It consists of 
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eight well-defined health regions and is considered to be representative for the 
Netherlands. We investigated all GBS cases admitted to the hospitals between January 1, 
1987 and December 31, 1996. 
Case-collection 
After obtaining permission from the neurologists in all 45 hospitals, medical records were 
collected of patients discharged under the international classification of disease code for 
GBS (ICD-9, 357.0). This code covers the following diagnosis: acute infectious polyneuritis, 
postinfectious polyneuritis, GBS and Miller Fisher syndrome. To exclude false-positive 
cases, each case was re-evaluated by a senior-neurologist using the NINCDS-criteria for 
GBS 17 . To screen for false-negative cases, records were reviewed of patients discharged 
under !CO-codes 357.8 (other specified inflammatory and tox"1c neuropathies) and 357.9 
(not-specified inflammatory and toxic neuropathies) in three randomly selected hospitals. 
These codes are considered to be the most reasonable alternatives when GBS-patients 
are erroneously discharged. 
For each patient data were obtained concerning age, sex, duration of admission, symp-
toms and signs, days to nadir, complications and functional grading score {f-score) at 
fixed points (nadir, two weeks, eight weeks and six months). The !-score is a disability 
scale often used in clinical trials concerning GBS 18 . The following preceding infections 
were scored from stool- and serological studies: Cjejuni, Cytomegalovirus, Epstein-Barr 
virus and Mycoplasma pneumoniae. 
Statistics 
We used the Poisson distribution for calculating 95% confidence intervals for the IR. 
Differences in IR regarding gender, age group or year of admission were calculated with a 
chi-square test without continuity correction. AI! calculations were petiormed using STATA 
5.0 for Windows 95 (Stata Statistical Software, Release 5.0, College Station, TX). A p value 
< 0.05 was considered to be significant. 
Results 
During the period under investigation the number of inhabitants increased from 3.8 million 
in 1987 to 4.2 million in 1996 (source; Statistics Netherlands). According to the !CO-code 
615 patients were discharged with the diagnosis GBS. After re-evaluation, 494 patients 
met the NINCOS-criteria and 116 patients did not. Among the latter group were patients 
with chronic inflammatory demyelinating polyneuropathy (n=24) and patients reporting a 
typical GBS-Iike pattern with symptoms and signs too weak to meet the NINCDS-criteria 
(n=18); 13 patient-files were not available. Eighteen of the 494 patients had to be excluded 
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because their domicile was outside the borders of the predefined area. Under the code 
357.8 and 357.9 no patients were identified meeting the criteria for GBS. Table 1 shows 
the characteristics of 4 76 patients analysed in this study. 
Table 1. 
Characteristics of the patients (n= 476) 
* number in parentheses is number of patients on which 
information was available 
The overall crude IR was U 8 per 100.000 inhabitants (95% Cl 1.08·1.29). The age-adjusted 
IR, using the European population as a standard 19, was 1.14/100.000 (95% Cl 1.04·1.24). 
The crude IR for men was 1.42 (95% Cl 1.26-1.59) and for women 0.94 (95% Cl 0.82-
1.09) (p=0.0001). TheIR per age group shows a linear increase with age (p<0.01) (figure 1). 
The IR from 1987 to 1996 shows only a slight (non-significant) decline over the years. Figure 
2 shows the seasonal distribution of the IR. No clear fluctuation was found although there 
was a slight increase in incidence in June and during most winter months. No clear (oppo-
site) peaks of occurrence for any of the four infections were found throughout the year. 
Discussion 
In this study we investigated the IR and seasonal fluctuations of GBS in the Netherlands. 
When evaluating epidemiological data based on population surveys it is important to 
consider the method of case ascertainment, the size of the population and the time period 
under investigation. We used accepted diagnostic criteria (NINCDS) with the reasonable 
assumption that all GBS patients are seen by a general practitioner and referred to a 
neurologist. We studied 476 cases recruited in a ten-year period resulting in one of the largest 
epidemiological studies on GBS worldwide. 
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The crude IR of 1.18/100.000 inhabitants and age-adjusted IR of 1.14/100.000 inhabitants 
found in this survey, are in agreement with other studies using NINCDS criteria. The gender 
difference in IR reaching a significant level has only been reported earlier in two studies 
where NINCDS criteria were used 3·10 . 
In our study we found a linear increase in incidence with age (p<0.01) without an additional 
peak around 20-30 years as has been described in other studies 1.4·5·9·13·20-22 . Of those studies 
describing a linear increase with age 2·3•6·8·10· only one reached a significant level 2. 
In most studies, including ours, the reported IR over the years suggest that there is no 
change in incidence over time 1·15•20·21 . Although there is hardly ever a significant difference 
between seasons reported, there appears to be a slight lean towards studies reporting the 
occurrence of GBS more often in the autumn and early winter 1·3·8·11 •23 . Data in our study 
are also suggestive for the preference for the w'1nter months. We were unable to conf1rm 
the suggestion that a clear lack of seasonal preponderance is due to the occurrence of 
specific infections since the most frequent antecedent infections we have studied did not 
show opposite seasonality 16 . 
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Figure 1. Incidence rates per age group 
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Abstract 
Background: Over the years, an increase in the number of Guillain-Barre syndrome (GBS) 
patients has been observed in Curagao, the Netherlands Antilles. 
Methods: Clinical and serological data were obtained from records of patients, admitted bet-
ween 1987 and 1999 and fulfilling the NINCDS criteria for GBS. When possible, serum and stool 
samples were collected. The results were compared with a large Dutch epidemiological study. 
Results: Forty-nine patients were identified resulting in an overall crude incidence rate (lR) 
in Cura9ao of 2.53/100.000 inhabitants (95% Cl 1.87-3.35) (Dutch study 1.18, rate ratio 
(RR) of 2.14, p<0.001). TheIR in Curagao increased from 1.62 in period 1987-1991 to 3.10 
in the period 1992-1999, RR 5.22 (95% Cl2.48-10.2, p=0.02). TheIR showed a curved 
linear shape within a year. In comparison with the Dutch group, patients from Curagao 
were characterised by a more severe course of the disease with a mortality rate of 23% 
(3.4% in the Dutch group, p<0.001), a higher percentage of preceding gastro-enteritis 
(p<0.001) and less involvement of the sensory system (p<0.001). In eight of ten serum 
samples evidence was found for a recent infection with Campylobacter jejuni. 
Conclusion: This study reports a steady increase in incidence of GBS over the years in 
association with a more pronounced seasonal preponderance and a more severe course. 
The clinical characteristics suggest a role for C.jejuni. An isolated island population is an 
excellent base to study a multifactorial disease of unknown pathogenesis. 
Introduction 
Over the years the Guillain-Barre syndrome has shifted from a single entity of an acute flaccid 
paralysis with absent tendon reflexes to a spectrum of subgroups within the broad clinical 
definition. Studying these subgroups, based on clinical, pathological, electrophysiological 
or epidemiological findings, may help to unravel the etiology of GBS. Epidemiological 
phenomena are important since they can contribute to a better understanding of 
pathophysiological mechanisms. 
Here, we describe a study on the occurrence of GBS on the island Curayao, one of the 
Netherlands Antilles. In recent years there appears to be an increase in the number of GBS 
patients in Curayao and the individual cases seem to be characterised by a more severe 
course. We compared epidemiological, clinical and serological features of the GBS cases from 
Cura9ao with a control group of GBS patients from the Netherlands. Studying an increase in 
incidence of a rare, multi-causal disease in an isolated population could lead to more insight 
in its pathophysiological mechanisms and detection of possible unknown co-factors. 
pagina 39 
Chapter 2 
Methods 
The area and time-period 
The study was carried out in Cura<;ao, one of the five islands of the Netherlands Antilles. 
Curagao is an autonomous part of the Dutch Kingdom and more than 95% of the population 
has the Dutch nationality. This island is located near the cost of Venezuela and has a 
population of approximately 150.000. We studied all GBS cases admitted in the only 
neurological department on the island from January 1, 1987 to April 31,1999. 
As a control, we used data from a large population survey in the Netherlands. That study 
included all cases that were admitted between January 1, 1987 and December 31, 1996 in 
all 45 hospitals in the Southwest part of the Netherlands (4.2 million inhabitants) 1• 
Collection of cases and controls 
Medical records were collected of all patients discharged under the international classifi-
cation of disease code for GBS (ICD-9, 357.0). This code covers the following diagnoses: 
acute infectious polyneuritis, postinfectious polyneuritis, GBS and Miller Fisher syndrome. 
To exclude false-positive cases, each case was re-evaluated by a senior-neurologist using 
the NINCDS-criteria for GBS 2 . To screen for false-negative cases in Cura<;ao, all records 
were reviewed of patients discharged under ICD-codes 357.8 (other specified inflammatory 
and toxic neuropathies) and 357.9 (not-specified inflammatory and toxic neuropathies). 
These two codes are considered to be the most likely alternatives when patients are erroneously 
discharged. In the Southwest Netherlands this was done in three randomly selected hospitals. 
Data were obtained regarding age, sex, antecedent events, neurological signs and symp-
toms, treatment, days to nadir, complications, duration of admission and functional grading 
score (f-score) at fixed points 3 . We used the following parameters to indicate the severity 
of the disease: artificial ventilation, rapid onset of the disease (being bed bound within four 
days after the start of weakness), severe maximum weakness (Medical Research council 
(MRC) sumscore < 40/60) and mortality. When possible, serum and stool samples were 
collected to screen for antecedent infections. 
We scored the preceding infections that are most frequently associated with GBS namely 
influenza- or influenza like illness, respiratory tract infection, gastro-enteritis or diarrhoea 
and other infections 4 . The CDC criteria for nosocomial infections 5 were used to define 
the antecedent infections that occurred within three weeks before start of first symptoms 
of GBS. The following infections were scored from stool- and serological studies: 
Campylobacter jejuni (stool and serology), Salmonella, Shigella, Yersinia, 
Cytomegalovirus (CMV), Epstein-Bar virus (EBV) and Mycoplasma pneumoniae. 
Data on C.jejuni infections among the general population were derived from the only labo-
ratory on the island where stool cultures are carried out. We collected 121 serum samples 
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from healthy inhabitants of Curayao for controls. Twenty-nine were collected in March 
1999, 40 in June 1999 and 52 in November 1999. 
Statistics 
We used the Poisson distribution for calculating the 95% confidence intervals for the IR. 
Differences in IR per gender or age group were calculated with a chi-square test without 
continuity correction. For graphical representation of the increase in incidence over the 
years in Curagao, we used the method of restricted cubic splines 6 . To analyse trends in 
the IR, multivariate Poisson regression was used with year-of-admission and month-of-
admission as variables. 
Differences in characteristics between cases from Curayao and the Southwest Netherlands 
were, depending on the data, univariately tested using the chi-square test without contin-
uity correction, Fisher's exact test or- the Wilcoxon-Mann-Witney U test 
All calculations were performed using STATA 5.0 for Windows 95 (Stata Statistical Software, 
Release 5.0, College Station, TX). A p value < 0.05 was considered to be significant. 
Results 
Population and patients figures 
In Cura9ao the number of inhabitants increased from 152,314 in 1987 to 152,694 in 1997 
(source; Statistics Netherlands). Since at the time of analysis the number of inhabitants in 
1998 and 1999 was not available, we used the number of 1997 as an approximation. 
From January 1987 to May 1999, 65 patients were discharged with the ICD-code for GBS. 
Fifty-six patients met the NINCDS criteria for GBS, seven had another diagnosis such as 
chronic inflammatory demyelinating polyneuropathy or radiculitis and two patients were too 
mildly affected to meet the criteria for GBS. Another seven patients had to be excluded 
because they were not inhabitants of Curac;ao. No cases were identified with code 357.8 
and 357.9 that met the criteria for GBS. In the Southwest Netherlands 476 patients met the 
criteria for GBS in the period 1987-1996, within a population of approximately 4.2 million 
inhabitants. 
Incidence rates 
We found an overall crude incidence rate (IR) of 2.53/100.000 inhabitants (95% Cl1.87-3.35) 
in Cura9ao. The IR in the Southwest Netherlands was 1.18/100.000, resulting in a rate 
ratio (RR) of 2.14 (95% Cl1.56-2.88, p<0.001). In Cura9ao, theIR for men was 
3.28/100.000 (95% Cl 2.21-4.69), for women 1.86/100.000 (95% Cl 1.12-2.90), RR 1.77 
(p= 0.03). Comparison with the IR per gender in the Dutch study showed no differences. 
The IR in Curagao increased with age (p=0.02). This linear increase in incidence with age 
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was also found in the Dutch study. 
Figure 1 shows the incidence rates from 1987 to 1999 lor Cura<;ao and the Southwest 
Netherlands. A model, using multivariate Poisson regression, showed a trend in increasing 
IR from 1987 to 1999 in Cura<;ao (p=0.09). Figure 2 shows the IR per month. In contrast to 
the situation in the Netherlands, GBS is more prevalent in the months January, February 
and December in Curac;ao with a decline towards zero in the months April, May and June. 
Figure 1 
Incidence rate of GBS in 
Curac;:ao and the Southwest 
Netherlands, 1987-1999 
Figure 2 
Incidence rate per month in 
Curac;:ao and the Southwest 
Netherlands 
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Table 1 shows the characteristics of the patients in Cura<;ao and the Southwest 
Netherlands. The frequency of characteristics representing the severity of the disease 
(artificial ventilation, rap'1d onset of disease, maximum weakness, and mortality) are all sig-
nificantly increased in the Curayao group. Ten patients died in the Curayao group, 18 to 
120 days alter start of weakness. The age varied from 36 to 86 years, they had no severe 
concomitant diseases and were all treated with IVIg. All ten patients were admitted to the 
intensive care unit and monitored. In five patients autonomic dysfunction was reported. 
Six patients were transferred to the neurological ward because they showed sufficient reco-
very. Alter 1-7 days they were found death in bed or died alter unsuccessful reanimation. 
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Table 1. 
*Number of patients from which information was available 
**Characteristics representing the severity of the disease {described under 'methods') 
Preceding infections 
Table 2 shows the reported preceding infections in the patient group from Curayao and the 
Netherlands. Fifty-five percent of the patients in Cura9ao reported a gastro-enteritis as 
preceding infection. In eight of ten patients, serological evidence was found for a recent 
infection with C.jejuni. One of the two negative patients had a borderline antibody titer. 
From the faeces of that patient, C.jejuni was cultured. 
Table 2. Preceding infections in GBS patients from Cura<;:ao and the 
Southwest Netherlands 
* Number of patients from which information was available 
N.P. =not erformed 
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Additional analysis of Curac;ao cases 
From these results, three observations stand out Firstly, it appears that the IR runs a more 
or less stable course from 1987 to 1991, while from 1992 the IR starts to increase (figure 
1). Secondly, analysis of the preceding infection resulted in a high percentage of gastro-
enteritis in the Curagao group. Finally, in contrast to most other studies, we observed a 
seasonal fluctuation (figure 2). We investigated these three findings in more detail. 
We compared the group of patients diagnosed in the stable years (n= 12,1987-1991) with 
the group admitted during the years in which the IR increased (n=37, 1992-1999). The 
overall IR from 1987-1991 was 1.62 (95% Cl 0.36-2.83), the overall IR from 1992 to1999 
was 3.10 (95% Cl 2.18-4.27), RR 5.23 (p=0.02). Table 3 shows the clinical characteristics 
of the two periods. Regarding the preceding infections, a difference was found in the 
percentage of gastro-enteritis (36% in 1987-1991,61% in 1992 to 1999, p=0.19). 
Table 3. Characteristics of patient group 1987-1991 and 
1992-1999 
i i 
We compared the characteristics of both periods with the group of patients from the Dutch 
study. For the period 1987-1991, there were only differences found for the percentage of 
sensory involvement (25% in Cura9ao 1987-1991 versus 67% in the Southwest 
Netherlands, p=0.004) and rapid onset of weakness (75% in Cura9ao 1987-1991 versus 
32% in the SW Netherlands, p=O .02). For the period 1992-1999, besides a difference in the 
percentage of sensory involvement (15% in Cura9ao 1992-1999 versus 67% in the 
Netherlands, p<0.001), significant differences were found for all four characteristics repre-
senting the severity of the disease. Finally, a higher percentage of gastro-enteritis was 
reported in the 1992-1999 group (61% versus 20% in the Southwest Netherlands, p<0.001). 
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To explore the increase in reported gastro-enteritis among GBS patients, we collected 
data on positive C.jejuni stool cultures among the general population in Curayao. Data 
available from 1988 to August 2000, showed an increase in the number of positive cultures 
in 1999 and 2000 (n=1064, mean number 81). To explore the high percentage of serologi-
cally proven C.jejuni infections in the GBS patients, we analysed 121 serum samples from 
healthy controls from Cura9ao. Twenty-three of the 121 samples (19%) were positive for 
C.jejuniwhile in the GBS group, eight of the ten were positive (80%, p<0.001). 
In figure 2 the pattern of seasonality shows a curved linear shape with a peak in the 
months January, February and December and a decline towards zero in the months April, 
May and June. We used Poisson regression with restricted cubic splines to fit the IR per 
month and year in a model. Figure 3 shows higher IR over the recent years and a more 
pronounced seasonal preponderance. Inserting seasons instead of months into the model 
resulted in a low IR in spring (p=0.001) and summer (p=0.06) and no difference in autumn 
(p=0.19) compared to theIR in winter. To explore this seasonal preponderance, we analysed 
data on C.jejuni cultured from stools taken from the general population per month from 
1993-1999. Figure 4 shows the seasonal fluctuation of the number of cultured C.jejuni 
among the general population as well as the seasonal fluctuation of the GBS cases. 
Figure 3 
Incidence rate per year and month in Cura<;;ao 
O.S Incidence ratef100.000 
0.5 1999 
0.4 
0.3 
0.2 
0.1 
0 
jan feb mrt apr may jun jul aug sep oct nov dec 
month 
pagina 45 
Chapter 2 
Figure 4 
Number of cultured C.jejuni per month among general population in 
Cura<;:ao (1988-August 2000) and IR GBS per month (1987-1999) 
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Discussion 
This is the first study reporting an increase in incidence rate of GBS over a longer period 
associated with an increasing mortality rate, an increasing seasonal fluctuation and an 
increasing percentage of preceding gastro-enteritis. 
The first question however, is whether the increasing number of patients truly reflects an 
increase in JR of GBS. This study was performed retrospectively and for the complete 
study period, hospital discharge data and the NINCDS criteria were used. Screening hos-
pital discharge data is an accepted method for studying the epidemiology of a disease, 
provided that accepted diagnostic criteria are used and that the disease is likely to result 
in hospitalisation 7. This study was based on and identical in methodology to a survey 
performed in the Southwest Netherlands. In that study, 476 cases were analysed resulting 
in one of the largest epidemiological studies on GBS worldwide. Data of that study were in 
agreement with the literature on the epidemiology of GBS. In conclusion, we consider the 
study as performed in Curac;ao to be consistent, making it reasonable to assume that the 
increase in number of GBS patients truly reflects a rise in IR. 
Three other studies have reported an increase in IR of GBS over the years. In contrast to our 
study, in two studies no differences were found with regard to age, clinical characteristics, 
preceding infections or severity of the disease. It was concluded that the most plausible 
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explanation was chance occurrence 8·9 . The study from Ferrara, Italy, reported that the 
increase in incidence predominantly affected people over 50 years of age in urban centres 10 . 
In Curagao, we found an overall IR of 2.53 per 100.000 inhabitants. This is higher than 
most other studies including that in the Southwest Netherlands. The high IR in Curagao is 
mainly due to the increase starting from about 1992. An incidence rate as high as 3.10 
over a six-year period (1992-1999) has never been described. We found that men were more 
frequently affected than women (p~0.03). In three other studies using NINCDS criteria, this 
difference also reached a significant level 1·11 ·12 . The linear increase with age found in this 
study is in agreement with other studies 1·7•8•11 -13 although some studies describe a bimo-
dal pattern 14-16 . Studies on seasonal fluctuations often report a preference for the colder 
months but seldom reach a significant difference 8·11 ·14 . In China, a variant of GBS has 
been described which occurs mainly in summer 17 . This "Chinese paralytic syndrome" has 
been recognised for at least 20 years and affects predominantly children and young adults 
in rural areas. The study in Cura9ao is the first in which the seasonal preponderance is 
based on incidence rates with significant differences between the seasons. 
Despite the relatively low number of cases one could speculate about the cause of the 
incidence increase in Cura9ao. An increase in the occurrence of an infectious agent can 
result in an increase of the number of GBS patients. More frequent exposure to the pathogen 
or the introduction of a particular strain, which more often triggers GBS, can also be 
possible causes. 
C.jejuni is the most frequently reported antecedent infection in association with GBS 18"20 . 
We suggest that C.jejuni plays a crucial role in the increase of GBS cases in recent years in 
Cura9ao. Firstly, we found a higher percentage of gastro-enteritis associated GBS in recent 
years. Since evidence for a recent infection with C.jejuni was found in eight out of the ten 
recently collected serum samples, it is likely that this pathogen is the predominant cause 
of gastro-enteritis. There was no increase in the number of C.jejuni cultured between 1988 
and 1998 among the general population. This suggests that the increase in GBS cases is 
more likely to be induced by a more pathogenic strain than due to an increase in the 
occurrence of C.jejuni on the whole. The increase in the number of C.jejuni cultured 
among the general population in 1999 and 2000 could be due to the introduction of a 
new, more advanced culturing technique. Recently, a start was made to type the bacteria 
cultures in order to gain more insight in the spectrum of strains. 
The observation that GBS runs a more severe course with a higher mortality rate also 
points to C.jejuni since different studies report on the association between a preceding 
C.jejuni infections and a more severe course of GBS 18'21 -23 . In most studies, the pure 
motor variant of GBS accounts for 10-20% of all cases 20 . Because this subtype is also 
associated with a preceding C.jejuni infection, the 83% of pure motor cases we found is 
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again suggestive for the relationship with C.jejuni 20·24 . In "the Chinese paralytic syndrome" 
the pure motor variant was also more frequently found. A prospective study showed a sig-
nificantly higher percentage of serological proven C.jejuni infections in those cases com-
pared to healthy controls 25 . A final indication of C.jejuni as a key player is the seasonal 
fluctuation. Although the curve linear shape of the occurrence of C.jejuni very much 
resembles the pattern of the IR of GBS, this requires further investigation since it is based 
on numbers and not on incidence rates. Because not every C.jejuni infection results in the 
development of GBS, C.jejuni alone can not entirely account for the increase in IR of 
GBS. Therefore, a role for host factors and/or environmental factors must be considered. 
Prospective research in this isolated island population can be of great value in determining 
factors involved in the pathofysiological mechanism of the Guillain-Barre syndrome. 
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Clinical aspects of 
the GuiUain-Barre syndrome 
Chapter 3 
3.1 Mild forms of the Guillain-Barre syndrome; a retro-
spective study 
Based on the article "Mild forms of Guillain-Barre syndrome in an epidemiological survey 
in the Netherlands". van Koningsveld R., MD, Van Doorn P.A., MD, PhD, Schmitz P.I.M., 
PhD, Ang C. W, PhD, Van der Meche F. G.A., MD, PhD. Neurology 2000;54: 620-625 
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Abstract 
3.1 Mild forms of the Guillain-Barre syndrome; 
a retrospective study 
Objective: Determination of distinctive characteristics in GBS patients who are only mildly 
affected (able to walk unaided at nadir). 
Methods: Records of GBS patients admitted between 1987 and 1996 from all 45 hospitals 
in the Southwest of the Netherlands were evaluated covering a population of 4.2 million 
inhabitants. 
Results: Four hundred seventy-six patients met the NINCDS-criteria for GBS. Patients under 
50 years of age (p<0.01) and men (p~0.01) were more frequently found in the mildly affected 
group. In both groups a preceding infection was reported in 70% of the cases. In the 
severely affected group serological evidence for infections with C.jejuni, CMV, EBV and 
Mycoplasma pneumoniae was found more frequently than in the mildly affected group (41% 
vs.16%, p~0.001). 
Conclusion: Distinctive characteristics for mildly and severely affected patients were found 
regarding age, gender and preceding infections. This suggests that other infectious agents 
or host factors may be involved in mild forms of GBS. 
Introduction 
Information on subgroups, clinical course, treatment and the pathogenesis of GBS mostly 
derives from clinical trials including our own studies 1·2 . These treatment studies have 
been restricted to the more severely affected patients, i.e. patients unable to walk unaided 
at nadir (point in time of maximum severity of the disease). Therefore knowledge on GBS 
is mainly based on this subgroup of patients. 
Here, we report an epidemiological study, retrospectively performed over a period of ten 
years in the Southwest of the Netherlands. We assessed the clinical characteristics of the 
complete spectrum of patients from severely to mildly affected. Knowledge of factors limiting 
the disease may be of importance in unravelling its pathogenesis and the development of 
new treatments. 
Material and Methods 
Paragraph 2.2 gives detailed description of the methods used in this study. In addition the 
following information was used to study the differences between mildly and severely 
affected patients. 
Patients were considered to be mildly affected when the f·score was < 3 (able to walk 
unaided at nadir) and severely affected when the maximal f-score was~ 3 (unable to walk 
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unaided at nadir}. The f-score is a disability scale often used in clinical trials concerning 
GBS 3 . In the analyses of differences between mildly and severely affected patients, those 
with an f-score of 6 (dead) were left out (n=16). Inclusion of grade 6 patients in the severe 
group could lead to distorted results regarding the duration of hospitalisation, days to 
nadir and other factors related to the progression of symptoms. The scores 1 to 5 indicate 
a functional state which patients may reach due to GBS. Attainment of an f-score of 6 is 
not automatically due to progression and can also occur as a complication of the disease. 
Inclusion of grade 6 patients would not have influenced the results regarding the differen-
ces in serological proven infections between mildly and severely affected patients {see 
results section). 
Definition of events 
We scored the events most frequently associated with GBS namely cancer, surgery, 
vaccination and pregnancy 4-7 as positive when they occurred within three weeks before 
the start of the first symptoms of GBS. 
Data on preceding influenza- or influenza like illness, respiratory tract infection, 
gastro-enteritis or diarrhoea and other infections were obtained from chart reviews and 
were considered positive when patients reported symptoms meeting the criteria for these 
infections according to the CDC definitions for nosocomial infections 8 and when they 
occurred within 3 weeks before the start of the first symptoms of GBS. The following 
infections were scored from stool- and serological studies: Cjejuni (stool and serology), 
Salmonella, Shigella, Yersinia, CMV, EBV and Mycoplasma pneumoniae. 
Statistics 
Depending on the data, differences between mildly and severely affected patients were 
univariately tested using the chi-square test without continuity correction, Fisher's exact 
test or the Wilcoxon-Mann-Witney U test and multivariately using logistic regression. 
Outcome was adjusted for age and gender simultaneously using logistic regression. All 
calculations were performed using STATA 5.0 for Windows 95 (Stata Statistical Software, 
Release 5.0, College Station, TX). A p value< 0.05 was considered to be significant. 
Results 
Table 1 shows the characteristics of the 476 patients. For the total group, outcome at 8 
weeks and 6 months was worse for the group age 2: 50 years (both p<0.01 ). Women were 
less frequently able to walk independently after 8 weeks than men (p=0.06); this difference 
was not found at 6 months. In a multivariate analysis testing age and gender, only age had 
an effect on the ability to walk independently at 8 weeks (p<0.01) and at 6 months (p<0.01). 
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* number in parentheses is number of patients on which information was available 
F-score at nadir 
Figure 1 shows the distribution of days until nadir for the total group with a median of 
eight days (range 1-30 days). The median for the mildly affected group was 7 days and for 
the severe group 9 days (p<0.01 ). 
Figure 1. Days to nadir 
% 
10 20 30 
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We were able to obtain the f-score at nadir for 436 patients. One hundred twenty-one 
patients (28%) were mildly affected and 315 patients (72%) were severely affected (table 
1). Significantly more mildly affected patients were men (p=0.01) and below 50 years of 
age (p<0.01)(figure 2). In a logistic regression, age and gender both maintained their influ-
ence on being "mildly or severely affected at nadir" (age p<0.01, gender p=0.02). 
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Table 2. Antecedent events 
and infections 
* number in parentheses is number 
of patients on which information 
was available 
Figure 2. Mildly and severely affected patients per age group and gender 
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Antecedent events and infections 
Table 2 shows the events and infections preceding GBS in the total group. Seventy-two 
percent of the cases reported that an infection preceded the initial symptoms of GBS 
whereas in 33% a stool culture or serology was positive for one or more agents. Among the 
47 other clinically reported infections the following were reported more than once: pneu-
monia (7), cystitis (5). sinusitis (3) and otitis media (2), herpes zoster (2), varicella zoster (2). 
Table 3. Serological screening of infections in mildly and severely affected 
Mildly affected 
%positive 
* number in parentheses is number of patients of which serum sample was available 
There was no significant difference in reported infections for the mildly and severely affected 
patients (73% and 71% respectively). This is in contrast with the serological results where 
in the severe group 90 out of 220 (41 %) and in the mild group 9 out of 55 (16%) were 
positive (p<0.01, table 3). The results regarding C.jejuni stool cultures differed from these 
findings; in the mild group 7 of 29 (24%) cultured stools were positive whereas 6 of 100 
(6%) in the severe group (p<0.01). 
Multivariate analysis on the outcome of being mildly or severely affected now showed that 
age 2 50 years (p=0.06), men (p=0.07), presence of diarrhoea (p=0.09) and positive serology 
for C.jejuni, CMV, EBV or mycoplasma pneumonia (p=0.02) are more frequently associated 
with the more severe clinical course. 
Complications and recurrence 
Complications were found in 67 cases including 20 times autonomic dysfunction and 29 
complications reported during intensive care admission (pneumonia, atelectasis, deep 
venous thrombosis, sepsis). Sixteen patients died (3.4%). In 11 patients GBS reoccurred 
(2.5%) with a mean period of 16 months between the two episodes (2·47 months). One 
patient had three episodes of GBS (once in 1987, twice in 1991). There was no difference 
between the mildly and severely affected patients in recurrence rate. There appeared to be 
no relation between the severity of the first period and the chance of being mildly or 
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severely affected during the subsequent episode. 
Discussion 
In this study we described characteristics of mildly affected GBS patients versus severely 
affected patients. We found 28% of the patients to be mildly and 72% to be severely 
affected. In three other studies the percentages of mildly affected patients were respecti-
vely 19, 23 and 24 9- 11 . In our study, age and gender were related to the maximum severity 
of the disease and therefore the chance of being mildly or severely affected. No previous 
studies report on women being more frequently severely affected than men. There are 
however studies on CMV related GBS, that report a more severe course and a higher 
incidence in young women 12 . We tested this in a multivariate analysis and showed that 
there was no relationship between the predominance of women in our severe group and 
the presence of CMV infections. As in this study, older age is often described as a prog-
nostic factor for worse outcome 9 · 13 ~15 . This is the first study however reporting age as a 
predictor for a more severe course of the disease. Another finding which has not been 
earlier described is that women had a worse outcome at 8 weeks compared to men. In a 
multivariate analysis only age had influence on the ability to walk independently both at 8 
weeks (p<0.01) and 6 months (p<0.01 ). 
That more than 70% of the patients reported a preceding infection confirms the established 
consensus concerning the triggering role of infections in GBS 16-18 . Although C.jejuni 
infections are generally associated with a more severe clinical course 1'19•20 , we also found 
positive serology and positive stool cultures in the mildly affected group. Surprisingly, the 
percentage of positive stool cultures for C.jejuni was higher in the mild group. Additional 
information showed that in the mild group, stools were cultured on indication (most patients 
had a clinical gastro-enteritis) whereas culturing in the severe group was more often part 
of a standard procedure. Future prognostic studies are needed to show whether different 
strains of C.jejuni are responsible for the severity of GBS, and whether host factors further 
determine the course of the disease. Serological screening of the four most frequently 
reported antecedent infections resulted in significantly more positive patients in the severe 
group compared to the mild group (41% vs.16%). Considering the similar incidence of 
clinically reported infections, one may conclude that the common known infections preceding 
GBS are of less importance in mildly affected patients. 
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3.2 Infections and course of the disease in mild forms of 
Guillain-Barre syndrome 
Based on the article ulnfections and course of the disease in mild forms of Gui/fain-Barre 
syndrome". Van Koningsveld R., MD, Schmitz P.I.M., PhD, C. WAng, MD, PhD, Vander 
Meche F. G.A., MD, PhD, Van Doom P.A., MD, PhD. Accepted for publication by Neurology 
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Abstract 
Objective: Twenty-eight percent of the patients with the Guillain-Barre syndrome (GBS) 
remain able to walk unaided. Studying patients with the mild form of GBS can further 
contribute to knowledge of the spectrum of the syndrome and explore whether this 
subgroup may need treatment with IVIg. 
Methods: Patients fulfilling the NINCDS-criteria for GBS were included in a nation wide 
survey over a two-year period. Clinical characteristics and serum samples were collected 
prospectively. In addition, a questionnaire was filled in concerning the course and outcome 
of the disease. 
Results: We included a total number of 139 patients. Nineteen (14%) of the included 
patients were mildly affected, 120 (86%) were severely affected. Infections with Epstein-
Barr virus were found more frequently in mildly affected patients (p=0.02). The degree of 
severity of the disease between mildly and severely affected patients was different on the 
day of admission (p<0.01 ). Thereafter, the groups showed a remarkable similar rate of pro-
gression. The pure motor form of GBS occurred more frequently in the mild group 
(p=0.02). Thirty-eight percent of the mildly affected patients reported problems in the hand 
function and an inability to run at 3 and 6 months (all female, p=0.02). 
Conclusion: The difference in severity of GBS seems to be determined in an early phase 
of the disease. Preceding infections may influence the initial immune attack determining 
the severity of the disease. The presence of residual signs in patients with mild disease 
may advocate the use of early treatment in mildly affected patients. 
Introduction 
The Guillain-Barre syndrome (GBS) is a heterogeneous disease. Much effort has been 
made to describe subgroups of patients, primarily based on cohorts of severely affected 
GBS patients. Because the pathophysiological mechanism is not fully elucidated, it is not 
known which factors determine maximal severity, course of the disease and residual 
symptoms. 
Another subgroup, the mildly affected patients, comprise 5 to 28% of all GBS cases, and it is 
surprising how little information is available about this substantial group 1-5 . We previously 
performed a retrospective study on the group of patients who remain mildly affected, i.e. able 
to walk independently at nadir (maximum severity). However, due to the retrospective design, 
we were unable to study whether there were differences between the mildly and severely 
affected patients with respect to progression, the course of the neurological symptoms 
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and residual disability. In addition to a better insight in the pathophysiological mechanisms, 
further inventarisation might also give information whether mildly affected patients should 
be treated with intravenous immunoglobulins (IVIg). This is important since IVIg treatment 
is currently not given routinely to mild patients in most centers. 
We performed a 2-year nation-wide prospective study in which we gathered information 
on preceding infections, patients' characteristics including detailed information on the time 
course of neurological symptoms and signs, and the presence of anti-ganglioside antibodies. 
Material and Methods 
Patients 
From February 1998 to February 2000, all but three hospitals in the Netherlands participated 
in this study. After obtaining a written informed consent, the neurologists filled in a 
questionnaire for every new GBS patient and sent it, together with a serum sample to the 
investigators. Only patients fulfilling the National Institute of Neurological Disorders and Stroke 
criteria (NINCDS) 7 for GBS were included. For reasons of comparability, patients with the 
Miller Fisher variant (MFS) were excluded. At the end of the two-year study period, a 
questionnaire was sent to all patients. 
Preceding infections and anti-ganglioside antibodies 
The following preceding infections, judged clin·,cally, were scored prospectively: influenza-
or influenza-like illness, respiratory tract infection, gastro-enteritis or diarrhoea and "other 
infections". They were considered positive when patients reported symptoms meeting the 
criteria for these infections according to the Center of Disease Control (CDC) definitions 
for nosocomial infections 8 and when they occurred within three weeks before onset of the 
first symptoms of GBS. Based on earlier studies, we tested the presence of infection with 
C.jejuni, cytomegalovirus (CMV) and Mycoplasma pneumoniae serologically as described 
before 9 . Screening for Epstein-Barr virus (EBV) infection was done using a commercially 
available lgM capture enzyme-linked immunosorbent assay (Biotest AG, Dreieich, 
Germany). The assay was periormed according to the instructions of the manufacturer. We 
screened for lgG and lgM antibody reactivity against GM1, GM2, GD1 a and GQ1 b using 
ELISA as described previously 10 
Characteristics of the patients and neurological signs and symptoms 
The following characteristics and neurological signs were obtained from the questionnaire 
sent by the neurologist: age, sex, sensory involvement, cranial nerve involvement, therapy 
and the worst score (!-score) on the Hughes' scale. We defined patients as "severely 
affected" when their worst f-score was 2:: 3 (unable to walk unaided at nadir). Patients were 
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considered to be "mildly affected" when their worst !-score was,; 2 (able to walk unaided 
at nadir). 
The course of the disease 
The following data concerning the course of the disease were obtained from the patient's 
questionnaire: presenting symptoms, time of onset of sensory symptoms (before, during 
or after start of muscle weakness), days until nadir, symptoms with which recovery started 
(less weakness of limbs, less sensory deficits, better speech, less ventilation problems). 
As most studies on GBS concern the severely affected patients (unable to walk at nadir), 
the course of the disease is mainly monitored with the Hughes' disability scale (!-score) 6. 
This scale focuses on mobility and therefore may not be sufficient to study the course of 
the disease in mild patients. We designed a questionnaire in which patients could score 
the course of the disease using four items: sensory symptoms, cranial nerve dysfunction, 
arm-hand disability and mobility. The Hughes' disability scale was used to represent the 
mobility 6 . Because this scale is used often and is validated, it was used to design the 
other three scales. Day 1 was defined as the day of the first symptom. Patients could rank 
their symptoms on a 0 (no symptoms) to 5 scale. With respect to the sensory symptoms, 
a score of 5 represented complete hypesthesiae on arms and/or legs. With respect to the 
arm/hand function and mobility, a score of 5 represented complete paralysis of the upper 
limbs and lower limbs respectively. With respect to cranial nerve dysfunction, patients 
could score on a 0 to 2 scale. A score of 0 represented no cranial nerve dysfunction, 1 
represented some double vision with or without facial nerve involvement, 2 represented 
complete ophthalmoplegia and/or facial nerve involvement. Before the questionnaire was 
sent, it was validated on a small group of patients. 
Outcome variables 
Sensory symptoms, cranial nerve deficits, hand-arm function and mobility were assessed 
at 1 ,2,3 and 6 months after the onset of the first symptoms. 
Statistics 
Differences in preceding infections, anti-ganglioside antibodies, characteristics, symptoms 
and signs and outcome between mildly and severely affected patients were tested using 
the chi-square test without continuity correction, Fisher's exact test or the Wilcoxon-
Mann-Witney U test where appropriate. The course of the disease was assessed with a 
questionnaire that was not fully validated. We used graphics to report these results and 
peliormed a generalised-estimating-equations-regression model to test differences bet-
ween mildly and severely affected patients while accounting for the correlated outcomes 
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due to the longitudinal design. In this model a first-order autoregressive structure for the 
correlation between the time-points appeared to be appropriate. All calculations were per-
formed using STATA 6.0 for Windows 97(Stata Statistical Software, Release 6.0, College 
Station, TX). A p value< 0.05 was considered to be significant. 
Results 
The patient group 
In the two-year period 158 patients entered the study. Three patients were excluded because 
they were misdiagnosed (chronic idiopathic demyelinating polyneuropathy, cervical stenosis 
and Lyme disease). Two patients were excluded because they died shortly after inclusion 
and no further information could be obtained. Fourteen patients were excluded because 
they had MFS. One hundred and twenty of the remaining 139 patients (86%) were severely 
affected and 19 patients were mildly affected (14%). The mean period between start of 
weakness and the time the patient-questionnaire was filled in, was 16 months (range 1-33 
months). This time window did not differ significantly between the mildly and severely affec-
ted patients. 
Preceding infections and anti-ganglioside antibodies 
Table 1 shows the preceding clinical infections, results from the serological infection stu-
dies and the presence of anti-ganglioside antibodies. There was no difference in the per-
centage of reported preceding clinical infections between the two groups except for the 
reported "other infections". These consisted of 1 patient reporting fever and 1 patient 
reporting pneumonia in the mildly affected group. In the severely affected group, 1 patient 
had an infection with Helicobacter pylori and 1 patient reported a paronychium. The 
results of the serological screening showed a difference in the percentage of preceding 
EBV infections (50% in the mild group and 23% in the severe group, p=0.02). Anti-gangli-
oside antibodies were found less frequently in the mildly affected group (p = 0.03). 
Characteristics and neurological signs 
Table 2 shows the characteristics and neurological signs for the total group and for the 
mildly and severely affected patients. More females (p=0.05) and patients under 50 years 
of age (p=0.01) were found in the mildly affected group. Furthermore, the pure motor vari-
ant was more frequently found in the mildly affected group (p=0.02). 
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Table 2 Characteristics and neurological signs 
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The course of the disease 
Figure 1 shows the course of the disease for the mildly and severely affected patients, 
expressed by the course of the sensory symptoms, cranial nerve deficits, arm-hand functi-
on and mobility. In all four items, a difference is already seen on day one, while the rate of 
progression between day 2 to day 14 is strikingly similar for both groups. 
There was no difference in presenting symptoms between the mildly and severely affected 
patients. Furthermore, there was no difference in time of onset of sensory symptoms bet-
ween the two groups (47% before, 27% during and 18% after onset of weakness, 8% 
unknown). Both groups reported a median time of 10 days (range 2-30) to reach nadir. No 
difference was found in symptoms with wh'1ch the recovery started. 
Figure 1 
Course of GBS during first 14 days for mildly and severely affected patients 
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Outcome variables 
There was no significant difference in sensory symptoms and cranial nerve dysfunction at 
1 ,2,3 and 6 months after onset of the disease between both groups. Figure 2 shows the 
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arm-hand function and mobility during the first 14 days and 1 ,2,3 and 6 months after 
onset of the disease. Even after six months, a considerable proportion of mild patients still 
had residual disability. 
Figure 2 
Arm-hand function and mobility (f-score) during six months in mild and 
severely affected patients. 
Scoro 
Discussion 
Arm-hand function 
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This study reports on preceding infections, anti-ganglioside antibodies, clinical characte-
ristics, course and outcome in patients with a mild form of GBS, compared with severely 
affected patients. Before interpreting our findings, it is important to discuss whether the 
study population is representative. 
Based on the incidence rate of GBS in the Netherlands (1.18/1 00.000), the 158 patients 
that entered the study in two years cover about 50% of the total number of expected 
patients. Although almost all hospitals agreed to participate in this study, a number of 
large centres did not report any patients to the investigators. This suggests a selection 
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bias at hospital level more than a selection at patient level. The percentages of preceding 
infections, characteristics and neurological signs for the total group (table 1 and 2) are 
similar to the figures reported in earlier studies except for the high percentage of positive 
EBV serology 5·9·"- We found 14% of the patients to be mildly affected in contrast to the 
28% reported in our previous (incidence-based) study 5 . The fact that we excluded the 
MFS patients additionally contributes to the lower percentage on which we report here. 
Taken together, we consider this study population representative although the percentage 
of mildly affected patient might be underestimated. 
We confirmed the similar distribution of clinical infections between the mild and severe 
patient as reported in the Dutch epidemiological study s Not only in the mild group (50%), 
but also overall (27%) we found a higher percentage of preceding EBV infections. 
Because in the present study, a different assay to detect EBV infections was used, we 
validated the assay with a group of control sera (n=86). This control group showed a low 
percentage of positive EBV serology (3.5%) and the difference with the overall percentage 
in the GBS group was highly significant Although it needs to be confirmed, this study 
suggests that an infection with EBV more frequently results in a mild form of GBS. 
Except in MFS patients, there are no studies available on the presence of anti-ganglioside 
antibodies in GBS patients with only mild weakness. We found a striking absence of anti-
ganglioside antibodies in mild patients. Earlier studies, mostly based on severely affected 
patients, describe an association between the antecedent C.jejuni infections, anti-GM1 
antibodies and the pure motor form of GBS ,_,._ In the mildly affected group we found no 
patients with anti-GM1 antibodies, but a high percentage of patients had the pure motor 
variant. Furthermore, the distribution of preceding C.jejuni infections did not differ between 
the groups. It appears that the pure motor variant in the mildly affected patients in this study 
does not result from a preceding C.jejuni infection and the generation of anti-GM1 antibodies. 
As described in earlier studies, we found an association between the presence of anti-
GQ1 b antibodies and ophthalmoplegia in the total group 15·''- Despite the presence of 
ophthalmoplegia in the mild group these patients did not have any anti-GQ1 b antibodies. 
Because the Hughes' disability scale measures mobility problems in GBS patients and we 
were particularly interested in mildly affected patients, we suggested that it was probably 
more accurate to measure the course of the disease using four items. Do the results as 
shown in figure 1, inform us about the course and possible pathophysiology of mild versus 
severe patients? When interpreting the results it is important to realise that most mildly 
affected patients were not treated while most severely affected patients did receive treatment. 
This may have influenced the course. However, there is a consistent repetitive difference 
between mildly and severely affected patients in all four graphs. This could suggest a 
difference in initial immune attack. However, based on the current data it is not possible to 
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distinguish whether this is due to a difference in preceding agents, the presence anti-
ganglioside antibodies or to yet unidentified hostfactors. The difference in distribution of 
preceding infections with EBV and anti-ganglioside antibodies in the mild and severe group 
suggest that these factors may play a role. While the graph on mobility problems (Hughes" 
disability scale) highly resembles the other figures, it may be concluded that the other three 
items provide little additional information. 
ln contrast to our expectations, mildly affected patients reported considerable mobility 
problems. One randomised clinical trial showed the effectiveness of plasmapheresis in 
mild patients "- Considering the reported residual signs in mildly affected patients and the 
effectiveness of IVIg 18 , it seems appropriate to investigate this treatment in this group of 
patients. 
We can conclude that mildly and severely affected patients show differences in preceding 
infections and anti-neural immune response. The course of the disease showed remarka-
ble and consistent differences between the two groups, suggesting that the severity of the 
disease is determined in a very early phase. Finally, the residual complaints in patients 
who are only mildly affected warrant studies on treatment with IVIg in mildly affected GBS 
patients. 
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Meche F.G.A., MD, PhD, Van Doorn P.A., MD, PhD. Submitted 
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3.3 Course of the disease and treatment evaluation 
in the Miller Fisher syndrome 
Objective: The Miller Fisher syndrome (MFS) is considered to be a benign variant of the 
Guillain-Barre syndrome (GBS). However, no studies are available focussing on the course of 
the disease and outcome in MFS. Because MFS has a low incidence rate, information on 
treatment of MFS is anecdotal and mainly derives from case-reports. We describe the 
course and outcome in a prospectively collected group of MFS patients. Together with a 
review of the literature, we aim to provide a better basis for treatment evaluation in MFS 
patients. 
Methods: Patients fulfilling the NINCDS-criteria for GBS and MFS patients were included 
in a nation-wide survey in the Netherlands over a two-year period. From all patients, clinical 
characteristics and serum samples were collected prospectively. In addition, a questionnaire 
was filled in by the patients concerning the course of the disease and outcome. 
Results: Twelve MFS patients were included. Although less severe, the progression rate 
and the course of the disease were similar to that in GBS patients. At three and six 
months, 20% of the MFS patients reported problems with mobility. The review of the 
literature indicated favourable results of treatment in most MFS patients. 
Conclusion: The course of the disease in MFS clearly resembles that of GBS patients. 
Because of the low incidence rate of MFS, a randomised trial does not seem feasible, while 
IVIg and PE treatment are proven to be beneficial in GBS patients. It seems plausible to 
consider treatment in at least the severely affected MFS patients, despite the lack of solid 
evidence in this subgroup of patients with an immune-mediated polyneuropathy. 
Introduction 
In 1956, Miller Fisher described three patients with a clinical picture of external 
ophthalmoplegia, severe ataxia and areflexia 1 . It was not until a rise in the cerebrospinal 
fluid protein level in the third patient was found, that he suspected a close relation with 
the Guillain·Barre syndrome (GBS). Since then, the triad of external ophthalmoplegia, 
severe ataxia and areflexia was named after Miller Fisher and was considered a benign 
variant of GBS. Describing MFS as benign appears to be based more upon clinical expe-
rience and case reports rather than on the results of large clinical studies. The course of 
the disease and the outcome has never been the main focus of studies reporting on MFS. 
It is therefore unknown whether there is a ground for standard therapy with plasmapheresis 
(PE) or intravenous immunoglobulin (IVIg) in these patients. Because MFS is a rare disease, 
conducting a randomised trial would be difficult to manage within a reasonable number 
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of years or centres. 
Here, we report a prospective study on the course and outcome in MFS together with a 
review of the literature on the effect of treatment in patients with MFS. 
Material and Methods 
This study is part of a large nation-wide prospective study on GBS in the Netherlands. 
Detailed information is described in paragraph 3.2. From February 1998 to February 2000, 
patients fulfilling the National Institute of Neurological Disorders and Stroke criteria 
(NINCDS) 2 for GBS and patients with MFS were included. Based on the triad of external 
ophthalmoplegia, severe ataxia and areflexia, the MFS patients were selected and GBS 
patients were used as control group. We prospectively collected serum samples and 
information concerning preceding infections, neurological signs, age and sex of the 
patients. At the end of the study a questionnaire was sent to all patients. Hereby information 
was collected concerning the course of the disease including presenting neurological 
symptoms and outcome. Patients were asked to score the course of the disease during 
the first 14 days after onset of the disease using four different items (sensory symptoms, 
cranial nerve deficits, arm-hand disability and mobility). Patients could rank their symptoms 
on a 0 (no symptoms) to 5 scale. With respect to the sensory symptoms, a score of 5 
represented complete hypesthesiae on arms and/or legs. With respect to the arm/hand 
function and mobility, a score of 5 represented complete paralysis of the upper limbs and 
lower limbs respectively. With respect to cranial nerve dysfunction, patients could score 
on a 0 to 2 scale. A score of 0 represented no cranial nerve dysfunction, 1 represented 
some double vision with or without facial nerve involvement, 2 represented complete 
ophthalmoplegia and/or facial nerve involvement. 
Depending on the data, differences between MFS and GBS patients were univariately 
tested using the chi-square test without continuity correction, Fisher's exact test or the 
Wilcoxon- Mann-Witney U test. All calculations were performed using STATA 6.0 for 
Windows 97 (Stata Statistical Software, Release 6.0, College Station, TX). A p value< 0.05 
was considered to be significant. 
Results 
In the two-year period 12 patients fulfilled the criteria for MFS and 140 fulfilled the criteria 
for GBS. Table 1 shows the characteristics of the ten MFS patients on which suffident 
information was available. No difference was found in the percentage of reported prece-
ding clinical and serological positive infections between the MFS and GBS patients. 
Significantly more anti-GQ1 b antibodies were found in the MFS patient group. 
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Recovered 
Unable to 
run 
NB: NA= no serum sample available 
-=negative 
The MFS patients included seven men and three women aged 22 to 68 years (mean 41 ± 
16). In the MFS group 80% of the patients reported double vision and/or other cranial nerve 
problems as presenting symptoms, in the GBS group this was eight percent (p=0.09). 
The MFS patients reported a median time of 7.5 days to reach nadir, whereas a median 
time of ten days was reported by the GBS group (p=O. 71 ). 
With respect to the course of the disease in the first 14 days, there was a significant 
difference in the severity of cranial nerve deficits between the MFS and GBS patients. With 
respect to the sensory symptoms, arm-hand function and mobility, GBS patients reported 
more deficits at the first day. On the following days the progression at the three levels was 
remarkable similar between the GBS and the MFS patients. At week four and eight, more 
GBS patients reported sensory symptoms than MFS patients (p<0.01 ). At month three and six, 
this difference was not statistically significant. Four weeks after onset of the disease, 90% of 
the MFS patients reported to be severely fatigued. Six months after onset this was 50%, 
compared to 70% in the GBS patients (p=0.2). At six months more MFS patients reported 
cranial nerve deficits than GBS patients (p<0.01). Figure 1 shows the arm-hand function 
and mobility for MFS and GBS patients at the first 14 days, 1, 2 ,3 and 6 months after 
onset of the disease. One patient reported to be unable to run at three months and one 
patient reported to be bedbound at three months due to severe ataxia (20%). The latter 
patient reported to be only able to walk with help at six months (1 0%). 
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Figure 1 Arm-hand function and mobility (f-score) during six months in MFS 
and GBS patients. 
0 " 
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* 0-5 scale to indicate the level of paralysis in arms or legs 
In this study eight of the ten patients were treated with IVIg, the remaining two patients were 
untreated. The treated patients were younger than the untreated (p=0.01). No difference in 
sex and f-score at nadir was found between the treated and untreated patients. Table 2 
gives an overview of the available studies reporting on treatment results in MFS patients. 
* the two patients recovered but developed bilateral facial palsy 
** the patient recovered but developed occipital infarction 
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Discussion 
In this study we described the course of the disease and outcome of 12 prospectively 
included MFS patients. The reported preceding infections were diverse and thereby 
mimicking the distribution of infections in GBS. Berlit et al. reviewed clinical characte-
ristics, preceding infections and long-term outcome in a number of small studies with a 
total of 223 cases 3 . There, a respiratory tract infection was by far the most common site 
of a preceding infection in MFS. As reported previously 4:5 , we found a high percentage of 
anti-GQ1 b antibodies although these were not specifically associated with a preceding 
C.jejuni infection. 
The high percentage of male and the relative young age of onset are comparable with other 
studies 3 . With respect to the course of the disease, it is not surprising that MFS patients 
report significantly more often cranial nerve deficits as GBS patients do. The similar pattern 
of progression in MFS and GBS patients is remarkable. This may suggest an underlying 
similar pathophysiological mechanism. With respect to outcome, a considerable percentage 
of MFS patients reports problems at three and six months, among which the problem of 
fatigue. Realising that these patients were almost all treated, these residual signs could 
have been worse without treatment. The reported residual signs can thus be an argument 
in favour of treatment of MFS patients. Besides, other findings must be considered in the 
evaluation of treatment in MFS patients. The similarity in the course of progression confirms 
the opinion that MFS is a (relatively mild) clinical variant of GBS and the benefit of IVIg or PE 
treatment in GBS patients is widely accepted. The French Cooperative Group on Plasma 
Exchange in GBS, even showed benefit of treatment in mild patients 6. Another argument 
in favour of treatment is the fact that in one third to 50% of the patients, in whom the 
disease initially started as MFS, progresses to prominent muscle weakness and in some 
cases the need for artificial ventilation ?;S. Finally, almost all studies described in table 2, 
report favourable results of treatment. However, these results must be interpreted with 
caution because no control group was involved and it was not always described in what 
way the treatment effect was assessed. Additionally, it is not known how many MFS cases 
are treated without publication of the negative effect. In the evaluation one should be 
aware of this publication bias. 
The randomised controlled trial (RCT) is widely accepted as the optimal way to study 
treatment effect. Unfortunately MFS is a rare disease, which makes it difficult to conduct a 
randomised trial within a reasonable number of years and reasonable number of participating 
centres. 
The purpose of this study was to describe the course and outcome of MFS patients and 
draw attention to the issue whether these patients should be treated. Because treatment 
has never been evaluated by a RCT, reliable evidence is lacking. However, because of the 
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arguments stated above, of which the similarity in course of the disease with GBS is an 
important one, it seems attractive to treat MFS patients, especially those who are severely 
affected. 
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Randomised Controlled Trials in 
the Guillain-Barre syndrome 
Chapter 4 
4.1 Randomised trial on the additional effect of methylp-
rednisolon on standard treatment with intravenous 
immunoglobulin in Guillain-Barre syndrome 
Based on the article "Randomised trial on the additional effect of methylprednisolone 
on standard treatment with intravenous immunoglobulin in Gui!lain-Barre syndrome'. 
Van Koningsveld R., MD, Schmitz P.I.M., PhD, Visser L.H., MD, PhD, Vander Meche F.G.A., 
MD, PhD, Van Doorn P.A., MD, PhD and the Dutch Gui/lain-Barre syndrome study 
group* 
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Abstract 
Background: Intravenous immunoglobulin (IVIg) is an effective treatment in patients with the 
Guillain-Barre syndrome (GBS). Despite IVIg treatment morbidity is still considerable and 
mortality is 3-5%. Based on the positive results of a pilot study, we conducted an 
international. multicenter, double blind, placebo-controlled study on the additional effect 
of methylprednisolon (MP) on standard treatment with IVIg. 
Methods: All patients were treated with IVIg (0.4 g/kg of bodyweight) and randomised to 
receive intravenous MP (500 mg) or placebo for five consecutive days. Patients were only 
included when they were unable to walk unaided for ten meters and were still within their first 
14 days from the onset of weakness. Because age is a recognised prognostic factor, patients 
were stratified for age < or ::::-. 50 years. Primary outcome was defined as improvement of one 
or more grades on the Hughes' disability scale, four weeks after randomisation, compared 
with the score at entry. 
Results: We analysed 225 patients on an intention-to-treat base and adjusted for the two 
age groups. The percentage of patients that reached the primary endpoint in the MP/IVIg 
group was 68% and in the placebo/IVIg group 56%, p=0.05. Including all prognostic 
factors (age, number of days before randomisation, MRC score at entry and CMV infecti-
on) in a logistic regression model, this p-value was 0.015. Although not significant, most of 
the secondary outcome measurements were in favour of the MP/IVIg treatment group. No 
considerable differences in side effects were found between the two treatment groups. 
Conclusion: GBS patients, unable to walk independently and treated within 14 days after 
onset of weakness, show faster improvement when receiving additional treatment with MP 
on standard treatment with IVIg. Furthermore, no considerable side effects were reported. 
Altogether, we advice to add MP to standard therapy of IVIg in patients with GBS. 
Introduction 
The Guillain-Barre syndrome (GBS) is acute immune-mediated polyneuropathy. With an 
incidence rate of 1-1.5 per 100.000 inhabitants, GBS is the most common cause of acute 
flaccid paralysis in the developed countries 1;2 . Although spontaneous recovery generally 
starts 2 weeks after the maximum weakness is reached, a large number of patients have 
residual deficits ranging from fatigue to complete paralysis of the lower limbs 3-5. 
Based on the suspected immune-mediated character of GBS the effects of several treat-
ments have been investigated. The efficacy of plasmapheresis (PE) was demonstrated in two 
large randomised controlled trials (RCT) 6'7 In both studies, improvement started earlier 
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and artificial respiration was less often required in the patients treated with PE. In 1992, the 
results of a Dutch RCT showed equal efficacy of treatment with PE and IVIg a In 1997, this 
result was confirmed by the PE/Sandoglobulin GBS trial group 9 This trial also showed that 
the effect of combined PE and IVIg treatment is not superior to PE or IVIg alone 9 Because 
treatment with IVIg is safer and more convenient than PE treatment, JVIg can now be 
regarded as a preferred treatment for patients with GBS 10:11 . 
Despite this, GBS is stm a severe disease with serious morbidity after 6-12 months 5;12 . 
Furthermore, many patients report to be severe fatigue 3. Therefore, the need for other 
therapeutic options is evident. Based on the positive results of a pilot study 13 , we conducted 
a double blind RCT on the additional effect of high-dose intravenous methylprednisolon (MP) 
on standard treatment with IVIg. We hypothesised that in the MP/IVIg group, relatively more 
patients would improve at least 1 grade on the Hughes'disability scale, four weeks after 
randomisation than in the IVIg group (primary endpoint). The Hughes' disability scale is a 
disability scale most often used in RCT concerning GBS 14. 
Patients and methods 
Patients 
All patients admitted in the 36 participating centers and fulfilling the NINCDS criteria for GBS 
were evaluated for randomisation 15. A patient was eligible when the onset of weakness was 
within two weeks, when he/she was unable to walk independently for ten meters {f-score at 
least 3) and had signed the informed consent form. Exclusion criteria were: age below six 
years, suffering from GBS before, a previous severe allergic reaction to properly matched blood 
products, a known selective lgA deficiency, pregnancy, steroid treatment, contraindications 
for steroid treatment, suffering from severe concurrent disease or an inability to follow-up. The 
protocol was approved by the ethics committee of every participating centre. 
Treatment 
All patients received treatment with IVIg (Gammagard SD, Baxter Healthcare, Hyland Division) 
which was started as soon as possible after randomisation. Patients received 0.4g IVIg 
per kHogram bodyweight per day for f1ve consecutive days. Treatment with MP or placebo 
had to start within 48 hours after start of treatment with IVIg. Patients randomised to receive 
intravenous MP, received a masked bag with 500 mg MP per day for five consecutive days. 
Children received 8 mg MP per kilogram bodyweight per day for five consecutive days 
(maximum 500mg/day). Patients randomised to receive only IVIg, received a masked bag 
with 1 OOml normal saline (placebo) for five days. 
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Outcome measures 
The primary endpoint was defined as the percentage of patients that improved one or more 
grades on the Hughes' disability scale four weeks after randomisation, compared with the 
score at time of entry. Secondary endpoints were the percentage of patients able to walk 
independently after eight weeks, time required to improve at least one grade on the Hughes' 
disability scale, time required to improve until independent walking, difference in grade on the 
Hughes' disability scale at six months and one year and difference in need and duration of 
artificial respiration. 
Based on the results of the first RCT on IVIg and the pilot study on the additional effect of 
MP 8 :13 , we estimated the chance to improve one or more grades on the Hughes' disability 
scale four weeks after randomisation 50% for the IVIg group and 70% for the IVIg/MP group. 
The two-sided alpha was set at 0.05 and the beta error at 0.2. Two interim analyses were 
planned. With these parameters it was calculated that 114 patients would be needed in each 
treatment arm. 
Assessments 
Cranial nerve dysfunction, the Hughes' disability score and the Medical Research Council 
(MRC) sumscore were measured every week during the first eight weeks after entry, every 
two weeks during week 9-14, every four weeks during week 15-26 and once at week 52 
6r until the patient reached the functional score of one or zero. The Hughes' disability 
scale is a seven point functional scale were 0 represents healthy, 1; minor symptoms and 
capable of running, 2; able to walk 10 meters or more without assistance but unable to 
run,3; able to walk 10 meters across an open space with help, 
4; bedridden or chairbound, 5; requiring assisted ventilation for at least part of the day, 
6; dead 14. The MRC sumscore was assessed in six bilateral muscles of arms and legs, 
yielding a sumscore ranging from 60 (normal) to 0 (quadriplegic) "-
Sensory symptoms were scored at entry, at 4, 8, 14, 26 and 52 weeks after randomisation. 
Additional studies included routine testing of blood, urine and cerebrospinal fluid; electro-
physiology; serological screening for preceding infections with C.jejuni, CMV, EBV and 
Mycoplasma pneumoniae, the presence of anti-ganglioside antibodies, and stool cultures 
for a preceding infection with C.jejuni. 
Adverse events 
The adverse events were monitored daily and evaluated each next visit. These adverse events 
included: respiratory tract infection, urinary tract infection, intravenous catheter sepsis, 
gastrointestinal bleeding, deep venous embolism, pulmonary embolism, serum glucose 
level >10 mmol/1, renal failure and delirium. Every major adverse event was reported as 
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soon as possible to the coordination centre. 
Randomisation procedure 
Based on the prognostic influence of age, randomisation was stratified according to age 
<or;;:: 50 years 8;9;18 . Furthermore, block randomisation was used with random block sfzes 
of 4,6 or 8. A 24h-telephone service provided randomisation numbers according to the 
randomisation list. The local hospital pharmacist prepared the trial medication corresponding 
with the trial number. 
Statistical analysis 
Percentages in independent groups were compared by the chi-square test (without correction 
for continuity) with and without adjustment for age. Mean values in independent groups 
were compared by the Mann-Whitney U test. The time to reach an endpoint was analysed 
by the method of Kaplan and Meier and the log-rank test. For multivariate analyses of the 
dichotomous endpoint, we used logistic regression. All analyses were performed on an 
intention-to-treat basis followed by a per protocol analysis with the personal-computer 
program STATA (version 6). 
Results 
Randomisation 
Between July 1994 and July 2000, 285 GBS patients were assigned for randomisation (figure 
1). Twenty-three patients could not be included because they did not meet the inclusion 
criteria. Twenty-nine patients could not be randomised because they met one or more 
exclusion criteria. The most frequently reported exclusion criterion was treatment with 
immuno-supressiva within one month before randomisation. Two hundred thirty-three 
patients were randomised of which eight had to be excluded from the analysis because no 
measurement at four weeks, the time of the primary end-point, was available. Table 1 shows 
the base-line characteristics for the two treatment groups. 
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Primary endpoint (table 2) 
In an overall ITI analysis, 56% of the placebo group showed improvement of one or more 
grades on the Hughes' disability scale while this was 68% in the MP-treated group (p=0.06). 
After adjustment for the two age groups this p-value was 0.05 (odds-ratio 1.73, 95% Cl 1-3). 
For the per protocol analysis 20 patients were excluded, mostly because of minor treatment 
violations. Again 56% of the placebo group showed improvement of one or more grades 
on the Hughes' disability scale, in the MP-treated group this was 70%, p=0.03. After 
adjustment for the two age groups this p-value was 0.02 (odds-ratio 1.96, 95% Cl 1-3.5). 
Table 2 Primary endpoint: percentage of patients that improve one or more 
*ITT: intention to treat analyses (n=225) 
PP: per protocol analyses (n=205) 
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Figure 1 Trial Profile 
Total patients considered (n= 285) 
Number of not-randomised Number of randomised 
patients (n=52) patients (n=233) 
Received IVIg and Received IVlg and MP 
placebo 
(n=117) (n=116) 
'~ '~ 
Number who did not Number who did not 
reach primary endpo'1nt reach primary endpoint 
(n= 4) (n= 4) 
,t. 
' 
If 
Number analysed for Number analysed for 
primary endpoint primary endpoint 
(n=113) (n=112) 
'It 'if 
Followed-up for Followed-up for 
52 weeks 52 weeks 
(n=102) (n=1 02) 
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Secondary endpoints (table 3) 
Table 3 shows the results of the secondary outcome measurements. None of the six variables 
showed a significant difference between the two groups. Figure 2 shows the Kaplan Meier 
curves of the proportion of patients that were unable to walk independent (f-score>2) until 
52 weeks (p=0.37). Figure 3 shows the proportion of patients that improved one or more 
functional grades during the 52 weeks of follow-up (p=0.15). 
I after weeks 
Number of days required to improve 21 days 
at least one grade on the Hughes' disability 
I 
56 days 
1=2 
3 grades 
3 grades 
1.00 
0.75 JVIgf MP 
IVIg/Piacebo 
0.50 
0.25 
0.00 L,,---------,.,-------,,,--------3,9--------,-" -
21 days 0.15 
28 days 0.37 
3 grades 0.41 
3 grades 0.37 
Figure 2 
Kaplan-Meier curves 
indicating the pro-
portion of patients 
who recovered to 
independent 
locomotion {f=2) 
during 52 weeks of 
follow-up 
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Figure 3 1.00 r 
Kaplan-Meier curves IVIg/MP --~-- ~-- l. 
indicating the pro- 0.75 
portion of patients IVIg/Piacebo 
that improved one J 0.50 or more grades on 
the Hughes' disabi-
lily scale during 52 0.25 
weeks of follow-up 
0.00 
0 14 26 39 52 
Weeks after onset of weakness 
Prognostic factors 
We pertormed univariate logistic regression on the following variables: treatment, sex, age 
< or;::;: 50 years, number of days between onset of weakness and randomisation, number 
of days from onset of weakness until f=4 was reached (only for f>3), sensory involvement, 
MRC-score at entry, preceding upper respiratory tract infection, diarrhoea, infection with EB\1, 
CMV, Mycoplasma pneumoniae or Campylobacter jejuni. The following variables showed a 
significant negative effect on the outcome: age ~ 50 years, less than 4 days between onset 
of weakness and randomisation, MRC-score < 40/60 at entry and a preceding infection 
with CMV. We included these variables, together with treatment in a multivariate logistic 
regression model. All variables showed a p-value < 0.01, including treatment (p=0.015). 
Major Complications 
In the placebo group four patients died. One patient died on the second day after randomi-
sation due to a subarachnoid hemorrhage. The second patient died 22 weeks after rando-
misation, due to an intracerebral bleeding. The third patient suffered from severe autonomic 
dysfunction resulting in hypoxic ischeamic encephalopathy and multi-organ failure. After 
discussion with the family it was decided to stop artificial respiration at four weeks after 
randomisation. The fourth patient died five months after randomisation due to a cerebra 
vascular accident after operation on a damaged aortavalve due to endocarditis. 
In the MP-treated group six patients died. The first patient died from a cardiac arrest on 
the second day after randomisation. The second patient died four weeks after randomisa-
tion due to a gastro-intestinal bleeding. The third patient was found dead nine weeks after 
randomisation while he was recovering from GBS, probably due to a cardiac arrest. The 
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fourth patient died three months after randomisation probably due to a cardiac arrest. The 
fifth patient died, five months after randomisation from sepsis. The sixth patient died 
seven months after randomisation due to a cardiac arrest. 
Minor complications 
A urinary tract infection was reported in 30% of the cases in the placebo group and 18% 
in the MP-group (p=0.02). A serum glucose level >1 Ommol/1 was more frequently found in 
the MP-group (21% versus 7% in the placebo group), p<0.01. With respect to autonomic 
dysfunction, hypertension was more frequently reported in the placebo group (13% versus 
2% in the MP-group, p<0.01). 
Discussion 
In this trial we investigated the additional effect of methylprednisolon on standard treatment 
with IVlg in patients with Guillain-Barre syndrome. Patients were included when they were 
unable to walk independently and were within the first two weeks of the disease. The pri-
mary endpoint was defined as the percentage of patients that improved one or more gra-
des on the Hughes' disability scale four weeks after randomisation, compared with the 
score at time of entry. 
Despite randomisation, some differences were found in the baseline characteristics between 
the two treatment groups that need to be taken into account while interpreting the results. 
The difference in sex distribution between the two groups probably did not influence the 
outcome since there is no indication in the literature that there is a difference in treatment 
response between men and women. What most likely influences outcome is the distribution 
of !-scores at time of randomisation. In the IVIg/MP group eight percent of the patients had 
an !-score of five while this was only one percent in the IVIg/placebo group. The fact that more 
severely affected patients were included in the MP group negatively affects the outcome and 
therefore the assessed treatment effect in the MP group could be underestimated. The 
Sandoglobulin GBS trial group reported that a shorter duration from onset of weakness to 
randomisation had a negative effect on the outcome at four weeks 9• In this study the 
median number of days between onset of disease and randomisation was six days for the 
placebo group and four days for the MP group, which again could result in an under-
estimation of the treatment effect in the MP group. 
In the previous trial comparing the effect of IVIg and plasma exchange 8 , the percentage that 
improved in the IVIg group was 53%. The outcome of 56% in the IVIg/placebo group in this 
study can therefore be regarded as a confirmation of the assessed effect in the former trial. 
The ITI analysis showed that 69% of the patients reached the primary endpoint in the 
IVIg/MP group, and 56% of the patients treated in the IVIg/Piacebo group (p=0.06). After 
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adjustment for age the p-value was 0.05. The PP analysis also showed improvement in 56 
% of the IVIg/Piacebo patients, but 70% improvement in the IVIg/MP group, p=0.03 (after 
adjustment for age P=0.02). The multivariate analysis, including all relevant prognostic 
factors, favoured the combination of IVIg/MP treatment even more (p=0.015). Taking further 
into account the effect of the distribution of baseline characteristics, the positive effect of 
the addition of MP on standard IVIg treatment seems convincing. However, the secondary 
outcome measurements indicate that this effect mainly has a short-term character. The 
Kaplan-Meier curves in figure 1 and figure 2 show that the additional effect of MP is 
predominantly in the first 14 weeks. Furthermore, the percentage of patients that improved 
to an f-score of two at week eight was still higher '1n the MP-group while this difference 
was not found at six months and one year after randomisation. 
We investigated the prognostic factors that proved to be of influence in earlier trials on 
GBS 8;9;16 . The effect of age~ 50 years, a low MRC score at entry and a preceding infection 
with CMV on a worse outcome were confirmed. As reported by the Sandoglobulin GBS 
trial group, we found that a shorter duration from onset of weakness to randomisation had 
a negative effect on the outcome at four weeks 9. Their suggestion that patients randomised 
in a later stadium, were closer to the onset of spontaneous recovery is likely to hold true 
in this study. We did not find a prognostic influence of gastro-enteritis or a preceding 
infection with C.jejuni. This confirms an earlier study in which the negative effect of a 
preceding infection with C.jejuni on outcome was only found '1n patients treated with PE 
and not in patients treated with IVlg 19 . 
With respect to the adverse effects, more death occurred in the MP-group. Since four of 
the six patients died more than eight weeks after randomisation it is unlikely that this is 
related to the drug under investigation. Of the minor complications, a serum glucose 
>10mmol/l was more frequently reported in the MP-group. Additional analysis showed that 
this effect was present in the first eight weeks and after that no significant difference was 
found in the two groups. The rise in serum glucose due to MP-use can therefore be regar-
ded as transient. 
We conclude that methylprednisolone added to the standard treatment of IVIg improves 
outcome in patients with GBS because it hastens recovery, especially in the first months 
after onset of the disease. Although this study offers new treatment possibilities for 
patients with GBS, the long term morbidity and mortality are still considerable. Therefore, 
the search for drugs that generate long-term effects has to continue. 
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Appendix 
The following investigators participated in the study: 
• J.A. van Leusden and M.M. Veering, Medisch Centrum Alkmaar, Alkmaar • R. Bijlsma and 
A. Hovestadt, Eemland Ziekenhuis, Amersfoort • C.H. Polman, J.J. Heimans and R.P.M. 
Strijers, Academisch Ziekenhuis Vrije Universiteit, Amsterdam • l.N. van Schalk, Academisch 
Medisch Centrum, Amsterdam • W.H.J.P. Linssen, Sint Lucas Andreas Ziekenhuis, 
Amsterdam • L. Harms, Medizinische Fakultat Charit€, Berlijn • M. Van Zandijcke and 
V. Scholle, Academisch Ziekenhuis Sint Jan, Brugge • P.Y.K. Van den Bergh and C.J.M. 
Sindic, Clinique Universitaire St. Luc, Brussel • R.A.J.A.M. Bernsen, Bosch Medicentrum, 
Den Bosch • J.T.J. Tans and A.W. de Weerd, Medisch Centrum Haaglanden, Den Haag 
• D.L.J. Tavy, Ziekenhuis Leyenburg, Den Haag • W.J. Feikema, Deventer Ziekenhuizen, 
Deventer • R.P. Kleijweg, Albert Schweitzer Ziekenhuis, Dordrecht • A. Vermeij, 
Diaconessenhuis, Eindhoven • J. de Jonge and K. Keizer, Catharina Ziekenhuis, Eindhoven 
• JAG. Geelen and G. Wilts, Medisch Spectrum Twente, Enschede • Th.J.M.Breuer, 
Sint Annaziekenhuis, Geldrop • F. Visscher and A.M. Boon, Stichting Oosterschelde-
ziekenhuizen, Goes • A.E.J. de Jager and T.W. van Weerden, Academisch Ziekenhuis 
Groningen, Groningen • P.J.J. Koehler and J.W. Vredeveld, Atrium Medisch Centrum, Heerlen 
• W. Hacke and E. Hund, Ruprecht- Karls Universitat, Heidelberg • J.C. Koetsveld-Baart, 
St. Streekziekenhuis Midden Twente, Hengelo • J.J.G.M. Verschuuren and A.R. Wintzen, 
Leids Universitair Medisch Centrum, Leiden • E. de Vries-Leenders, IJsselmeer Ziekenhuizen, 
Lelystad • M. de Baets and H. Kerkhoff, Academisch Ziekenhuis Maastricht, Maastricht 
• B.G.M. van Engelen, G.W. Padberg and H.M. Vingerhoets, Universitair Medisch Centrum 
St. Radboud, Nijmegen • J. Meulstee, M.J.J. Prick, W.I.M. Verhagen and C.W.G.M. 
Frenken, Nijmeegs lnterkonfessioneel Ziekenhuis Canisius-Wilhelmina, Nijmegen • H.A.W. 
Sinnege, Medisch Centrum Rijnmond-Zuid, Rotterdam • H.W.M. Anten, Maasland 
Ziekenhuis, Sittard • R.L.A.A. Schellens, Sint Elisabeth Ziekenhuis, Tilburg • L.H. van den 
Berg and H. Franssen, Universitair Medisch Centrum Utrecht, Utrecht • B.J. van Kasteren 
and J.A.P. Hiel, Sint Joseph Ziekenhuis, Veldhoven 
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4.2 Changes in referral pattern and its effect on outcome 
in patients with Guillain-Barre Syndrome 
Based on the short communication "Changes in referral pattern and its effect on outcome 
in patients with Guiflain-Barre Syndrome". Van Koningsveld R., MD, Van Doorn P.A., MD, 
PhD, Schmitz P.I.M., PhD, Vander Meche F.G.A., MD, PhD. Neurology 2007;56:564-566 
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Abstract 
Objective: A multicentre trial in the Netherlands showed equal efficacy of treatment with 
plasma-exchange (PE) and intravenous immune-globulin (lVI g) in patients with the 
Guillain-Barre syndrome (GBS). Since IVIg is also available in smaller centers it is no longer 
necessary to transfer patients for treatment purposes. In this study we investigated the 
change in referral pattern of GBS patients after publication of this study. Additionally, we 
compared outcome parameters of patients admitted in small centers with patients admitted 
in large centers to investigate whether the referral pattern has been appropriately adapted 
after the general availability of a new treatment (IVIg). 
Methods: Hospital records of GBS patients admitted to all 45 hospitals in the Southwest 
Netherlands (4.2 million inhabitants) in the period 1987-1990 and 1994-1996 (n=266) were 
reviewed. 
Results: In the second period, after the publication of the PE/IVIg trial, more patients in 
small centers were treated with IVIg (p<0.001). Before publication 40% of the patients was 
transferred to larger centers compared with 23% thereafter (p=0.05). High-risk patients 
were still transferred to large centers. There was no increase of complications in small 
centers after 1992 despite the decrease of referral to large centers. More complications 
were reported in large centers. This is explained by the higher percentage of severely 
affected patients admitted to large centers. 
Conclusion: The introduction of IVIg resulted in less patients being transferred from small 
to large centers while high-risk patients are still being transferred appropriately. This change 
in referral pattern of GBS patients has led to a more optimal use of different levels of care 
facilities. 
Introduction 
The Guillain-Barre syndrome (GBS) is an acute immune-mediated polyneuropathy charac-
terized by a flaccid weakness, reduced or absent tendon reflexes and, to a variable degree, 
involvement of the cranial nerves and the sensory system. The incidence rate varies from 
1-2 per 100.000 inhabitants per year and increases with age 1'2 
Two large randomized trials established the role of plasma exchange (PE) as a treatment 
option for GBS 3"- In 1992, a Dutch randomized trial showed equal efficacy of treatment 
with PE and intravenous immune globulin (IVIg) in patients with GBS '-This outcome was 
confirmed by a large trial studying the effect of treatment with PE, IVIg and combined 
treatment of PE and IVIg 6 . Because treatment with IVIg is straightforward, widely available, 
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well tolerated and less prone to complications than PE, it has since 1992 become the 
treatment of choice in the Netherlands. 
After 1992, we noted a decrease in the number of GBS patients referred to our hospital 
and other large centers. Since IVIg can be administered in small centers it was hypothesized 
that it was no longer necessary to transfer patients to larger centers for treatment purposes. 
In this study we investigated the change in treatment strategy and in referral pattern after 
the introduction of IVIg. Because GBS runs a rapidly progressive course and complications 
such as hypoventilation and autonomic dysfunction can occur, it is questionable whether 
it is a positive development not to transfer patients to large centers. To answer this, we 
also studied outcome parameters in the period before and after 1992, in patients admitted 
to small centers as well as large centers. 
Patients and methods 
This study was part of an epidemiological survey on GBS in the Southwest Netherlands 2 
In this survey patients were selected when they were discharged with the international 
classification of disease code for GBS (ICD-9, 357.0) in all 45 hospitals from 1987 to 1996. 
Patients fulfilling the National Institute for Neurological Disorders and Stroke (NINCDS) 
criteria for GBS were included in the analysis (n=4 76) 7 
To investigate the change in referral pattern we defined two periods in the analysis. In 
both periods a clinical trial was conducted making them comparable in that respect. 
Period 1 is the period in which the PEIIVIg trial was performed (January 1987 to January 
1990). Period 2 was the period in which a subsequent study was performed with combined 
IVIg and high dose methylprednisolone therapy (IVIg/MP trial) (July 1994 to December 
1996). In both periods we studied the differences in outcome between small and large 
centers (n=25, n=20 respectively). Because the median number of beds in the hospitals 
was 380, we defined hospitals with less than 380 beds as small centers. 
We used the following parameters to study outcome: walking independently after two 
weeks, eight weeks and six months, mortality and complications. As confounding factors 
we included age, sex, f-score at nadir 8 and therapy. 
Differences in treatment choice, referral pattern, outcome parameters and confounding 
factors were calculated with a chi-square test without continuity correction, or when 
necessary a Fisher's exact test or the Wilcoxon-Mann-Witney U test. All calculations were 
performed us'1ng STATA 5.0 for Windows 95 (Stata Statistical Software, Release 5.0, 
College Station, TX). A p value < 0.05 was considered to be significant. 
Results 
In the two periods under study, 266 patients fulfilled the NINCDS criteria for GBS. Table 1 
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shows the characteristics of the patient group. 
Figure 1 shows the choice of treatment in small centers in the two periods. In period 1, 
11% of the patients was treated with IVIg, in period 2 this increased to 53% (p<0.001). In 
period 1, 40% of the patients was transferred from small to large centers whereas in peri-
od 2 only 23% was transferred (p=0.05). 
* Number of patients on which information was available 
Figure 1. 
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Table 2 shows the outcome parameters in small and large centers for both periods. 
Analysis of the confounding factors in period 1 showed no differences in the distribution of 
sex and age between the small and large centers. There were fewer patients receiving 
therapy in small centers compared to large centers (p<0.001 ), but there were also less 
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patients severely affected in small centers (f-score eo3) (p<0.001). In period 2, no significant 
difference was found for the four confounding factors. Table 3 represents the distribution 
of maximum f-scores per period for small versus large centers. 
To study the effect of the change in referral pattern on outcome in more detail, we analysed 
the group of patients who are believed to be at highest risk when not appropriately referred 
to larger centers when necessary. These are the patients unable to walk independently or 
bedbound and are therefore especially at risk for the need of artificial respiration and the 
development of complications. In this high-risk group we also found that less patients 
were referred in period 2 and thus more patients stayed in small centers. Analysis showed 
no more complications or mortality in period 2 in the small centers, only one patient received 
artificial ventilation in a small center in period 2. 
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Discussion 
This study is part of a large population based survey performed in Southwest Netherlands 2 . 
In this survey we studied 476 cases recruited in a ten-year period resulting in one of the 
largest epidemiological studies on GBS world-wide. The figures from this survey are in 
agreement with data reported in literature. Therefore we assume that the data reported in 
this study are reliable and can serve as a basis to study the effect of publication of the 
PE/IVIg trial on the referral pattern and the outcome in GBS patients. 
In this study we found that less patients were referred from small to large centers during 
the second period. Because there were significantly more patients treated with IVlg in small 
centers, it seems reasonable to assume that the introduction of IVIg is an important cause 
for the change in the referral pattern. GBS is a rare disease and therefore not all neurologists 
in every hospital have the opportunity to become experienced with the unexpected course 
of the disease and the risk of hypoventilation and autonomic dysfunction. In general, it has 
been advised to refer GBS patients to large centers with experienced personnel working in 
the intensive care facilities 1;9. There is no study available reporting on the referral pattern 
in GBS and it is not known whether patients admitted in small centers do worse than those 
in large centers. This study showed that there are no important differences in the outcome 
parameters between small and large centers. In period 1, there were more patients able to 
walk independently after two weeks in the small centers and there were fewer complications. 
This can be entirely explained by a less severely affected group remaining in those these 
centers compared to the group admitted to large centers. In period 2, there were no 
differences in outcome between small and large centers except a higher percentage of 
complications found in large centers in period 2. This is compatible with the relatively high 
presence of severely affected patients admitted to large centers. We found no more 
complications and no increase in mortality in period 2 in the small centers. This indicates 
that high-risk patients are still being transferred appropriately. The fact that only one patient 
received mechanical ventilation in a small center in period 2 suggests that, although facilities 
for ventilation are available in small centers, it is a policy to transfer those patients to large 
centers. 
In conclusion, the publication of the PE/IVIg study has had important consequences in the 
management of GBS patients in the Netherlands. It resulted in a more selective referral of 
severely affected GBS patients to large centers. When the results of a treatment trial are 
likely to cause a change in the treatment of a large percentage of a patient group, one 
should realize that this could have consequences for the referral pattern. When this is 
appropriately adapted it can lead to a more optimal use of different levels of care facilities. 
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General Discussion 
The studies described in this thesis concern epidemiological and clinical aspects of the 
Guillain-Barre syndrome. It also includes the results of a randomised placebo controlled 
trial on the additional effect of methylprednisolone on standard treatment with intravenous 
immunoglobulin. By studying epidemiological and more clinically related phenomena, we 
aimed to get more insight in the mechanisms that cause the differentiation of GBS into 
subgroups. Describing and recognising the GBS subgroups, especially the mHd variant 
is furthermore important because the response to therapy and the long-term prognosis 
may differ. 
In this chapter the main findings of the studies will be discussed and suggestions for future 
studies will be made. First, some methodological aspects wHI be considered. 
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Methodological aspects 
The studies described in this thesis are based on patients that fulfilled the NINSCDS criteria 
for GBS 1 . These criteria were originally set up to investigate and control the large number 
of reported cases of GBS in association with the swine-flu vaccination. To prevent the 
inclusion of false-positive cases, rather strict criteria were defined. 
Although the use of these criteria in this thesis was necessary to make the results comparable 
with other studies in this field, there certainly are drawbacks to the application of these strict 
criteria. In the study on the incidence rate of GBS in the Southwest Netherlands for example, 
18 patients had to be left out of the analysis because symptoms and signs were too weak 
to meet the criteria. These patients probably suffered from a very mild form of GBS. 
Therefore the reported incidence rate of 1.18/1 00.000 inhabitants might be an underestimation 
of the true number of GBS cases in the Southwest Netherlands. In both the retrospective 
and the prospective study on mild forms of GBS, again only patients were included that 
fulfilled the NINCDS criteria. It is very likely that thereby a number of very mild patients were 
not included. Studying these very mildly affected patients might have further contributed to 
the assessment of characteristics that influence the course of the disease. Therefore, future 
studies should also consider inclusion of these very mildly affected patients. 
With respect to the study on Curagao some remarks must be made concerning the control 
groups. We used the data from the survey from the Southwest Netherlands to compare the 
distribution of characteristics of the Curayao patients, thus GBS cases from the Netherlands 
were used as control group. These Dutch patients did not derive from the same source 
population as the patients from Cura9ao, which would have been the optimal control 
group. However, the use of a control group of available patients from Curagao (e.g. the 
group of 12 patients diagnosed in 1987 to 1991) would not be feasible because the low 
number would generate too little power. The epidemiological characteristics of GBS are very 
similar in different studies from all over the world (chapter 1 ). Therefore it seems justified to 
use the Dutch patients as the control group. To interpret the high percentage of positive 
C.jejuni serology in the GBS patients on Cura<;ao, a control group was needed. The fin-
ding of a high percentage of positive C.jejuni infections was only available some months 
after the onset of disease. The need to obtain serum samples from the general population 
was not an issue until then. We took samples of around 40 sera in March, June and 
November 1999, while the ten samples from the cases were obtained randomly during 
1998 and early 1999. Certainly because the incidence of C.jejuni infections shows a sea-
sonal fluctuation (paragraph 2.3), the difference between the two groups could be the 
result of the above described difference in sampling-time rather than a true difference in 
the percentage of preceding C.jejuni infections. Currently, studies are undertaken to 
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investigate the relation between the incidence of C.jejuni and GBS prospectively. 
In this thesis two studies concern the mild forms of GBS. With the interpretation and 
comparison of the results of these studies, it is important to be aware of the different 
character of both studies. The first study was part of an epidemiological survey. The main 
purpose was to assess incidence rates on GBS in the Netherlands. The information was 
retrospectively collected from patient records and the assessment of the differences between 
mild and severe patients was done without defining the determinants beforehand. An 
important point here is that the numbers and percentages resulting from this study are based 
on a survey that covered all neurological departments in all hospitals in the Southwest 
Netherlands resulting in a large number of GBS patients. This makes the obtained numbers 
and percentages from this study representative which is not the case in the prospective 
study (paragraph 3.2). Here, the aim was to collect clinical and serological data and not to 
assess incidence rates. The cases were presented by participating neurologists implying that 
the composition of the study group depended on these neurologists. Therefore selection 
bias cannot be ignored in this study. In contrast with the retrospective study, the serum 
samples of all patients were prospectively and systematically collected and tested all 
together at once in the same laboratory setting. Overall, while interpreting the results and the 
discussion on the mild form of GBS, when it concerns the characteristics of the patients 
(age and gender etc.) one might consider valuing the findings from the retrospective study 
as more appropr'1ate. When it comes to the preceding infections, the data from the pros-
pective study seem to be more valid. 
The last remark concerns the use of the terms "retrospective study" and "prospective 
study" in the following discussion. The term "retrospective study" will be used to address 
to the study on mild forms as described in paragraph 3.1. The term "prospective study" 
will be used to address to the study on mild forms as described in paragraph 3.2. 
Epidemiology 
Epidemiology studies the distribution of a disease and assesses factors that influence this 
distribution. Information obtained from epidemiological studies can be utilised in several 
ways 2 . First, it can help to elucidate the etiology of a disease by combining epidemio-
logical data with information from other disciplines. Second, it can be utilised to evaluate the 
consistency of epidemiological data with etiological hypotheses developed either clinically or 
experimentally. Third, it can provide a basis for development and evaluation of preventive 
procedures and public health practices. 
Essential in the epidemiology is the matter of causation and causal inference. With our present 
knowledge and insights it has become clear that almost all diseases are multifactorially 
induced. Different attempts have been made to organise this complex process in order to 
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gain a better understanding of the occurrence of diseases. A rather simple but convenient 
concept is the host-agent-environment theory in which the occurrence of a disease is the 
result of the presence of an agent which causes the disease in a susceptible person, given 
certain environmental circumstances. A probably more realistic but more complex view of 
disease aetiology is the web of causation. In this concept all predisposing factors to a 
disease and their complex relations with each other and with the disease are considered. 
The last theory discussed here, proposed by Rothman 3 is the concept of sufficient cause 
and component causes. A sufficient cause is defined as a set of minimal conditions and 
events (component causes) that inevitably produces disease. A given disease is considered 
to have a fixed number of sufficient causes. If a component cause is a member of all 
sufficient causes it becomes a necessary cause. While at present too little information is 
available about different causes in most diseases, it might be too early for practical use of 
this concept. 
It appears that the use of the theories described above depends on the quantity of 
information that is available on a disease. In GBS, the pathophysiological mechanism is 
largely unknown but information is available on several factors involved in the occurrence. 
It seems therefore appropriate to use the host-agent-environment model to describe the 
mechanisms involved in the occurrence of GBS from an epidemiological point of view. We 
will regard the patient as the host and the preceding infections as the agent. 
Age 
As in many other studies 4-7 , we found a significant increase in incidence with age in the 
study on the IR of GBS in the Southwest Netherlands (paragraph 2.2). This finding could 
suggest an increase in host susceptibility with age, provided that a certain agent is present 
in a given environment. Unfortunately the incidence rate of (preceding) infections alters with 
age as well as the environmental factors. As in many other illnesses, age cannot be of 
assistance in formulating a hypothesis of causation in GBS. However, in the assessment 
of other causal relationships an adjustment must be made for age because the relation with 
the occurrence of the disease is often very strong. 
With respect to the subgroups considered here, an association is described between younger 
age and the mild group (paragraph 3.1. 3.2), the MFS patients (paragraph 3.3 and 8), the CMV 
group 9 and the Chinese paralytic syndrome 10 . The relation with the mild forms will be 
discussed separately. In most patients with MFS, anti-GQ1 b antibodies are present 11 :12 . It 
would be interesting to study the relation between the presence and/or quantity of anti-GQ1 b 
antibodies and age. If the level of anti-GQ1 b antibodies decreases with age this can 
possibly explain the presence of MFS in younger patients and contribute to the evidence 
that anti-GQ1 b antibodies indeed play a role in the pathofysiological mechanism of MFS. 
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Because in MFS patients the disease tends to run a mild course, age could be a confounding 
factor in the relation between MFS and the mild group. 
The fact that younger age is associated with CMV-related GBS might be explained by the 
fact that the incidence of CMV infection is higher at younger age. As in the MFS group. it 
would be interesting to investigate the relation between age and the presence of anti-GM2 
antibodies since the presence of these anti-ganglioside antibodies is associated with 
CMV-related GBS 13'14 
The Chinese paralytic syndrome almost only affects children and young adults in rural 
areas in the summer 10 . Until now, no clear explanation is found for this typical pattern. 
Because of the typical clinical pattern and age distribution. one could suggest that these 
patients in fact suffer from poliomyelitis. However, the hallmarks of poliomyelitis - inflam-
matory cells in the CSF and motor neurone loss in the spinal cord- are absent 10 . 
Gender 
In general. men are more frequently affected by GBS than women (paragraph 2.1. 2.2. 2.3). 
Because the numerous differences between men and women are not only biological but also 
from environmental origin, it is difficult to speculate about the origin of this gender differen-
ce and what it may learn about the cause and determinants of GBS. Because of the many 
differences between men and women, it is surprising that there is hardly any variation in 
this difference among the subgroups. One study in the United Kingdom 15 reported more 
men in the C.jejuni associated subgroup (not statistically significant). This could be explained 
by the higher incidence rate of C.jejuni infections among men 16 . 
Geography 
The geographical distribution of a disease represents not only climatically characteristics 
but also differences in race, religion and social economic status. Here again, it is difficult 
to determine what is host-related, environmental-related or agent-related. For example 
certain religions come together with a specific diet, which can be regarded as an environ-
mental factor. Also religion is highly associated with race, which is a factor that influences 
the host susceptibility. Finally. the occurrence of infectious pathogens, in case of GBS 
regarded as the agent, is very much determined by climatically conditions. Except for the 
described high incidence areas in China and Curac;ao, there is a striking similarity in the 
distribution of ep-Idemiological characteristics as incidence rate, age and gender in studies 
from all over the world (paragraph 2.1). From this. it is clear that following the host-agent-
environment theory, these three factors must be present everywhere. Unfortunately, it may 
well be possible that for every zone or place, a different combination of host-agent and 
environmental factors is needed to generate GBS. 
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Seasonal variation 
The interest in the seasonal pattern of the occurrence of GBS is probably induced by the 
high incidence of GBS cases in the summer in case of the Chinese paralytic syndrome and 
by the frequent presence of a preceding infection before onset of GBS. Infections are highly 
related to seasons, for example infections with C.jejuni, which show a peak in summer and 
early fall 16 . Fluctuations in incidence of a disease being related to difference in seasons 
can be explained not only by climatic differences but also by sociologic changes following 
the seasons. The simplest example is eating habits; barbecue-parties during the summer 
months. Except for a few reported trends in favour of the colder months of the year, no 
seasonal distribution is reported except in the Chinese paralytic syndrome and the patient 
group in Curagao (paragraph 2.1, 2.2, 2.3). In Curagao it is likely that the seasonal fluctuation 
of GBS is induced by the fluctuation of infections with C.jejuni within the year (paragraph 
2.3). This finding is highly suggestive for a role for C.jejuni as (one of the) agent in the 
occurrence of GBS and a unique example of an epidemiological finding that confirms and 
thereby strengthens a relationship which is previously described in other scientific settings. 
Earlier reports on the relation between C.jejuni infections and the occurrence of GBS were 
namely derived from laboratory studies 17-19 . 
Conclusion and direction for future research 
With the use of models of causality, an attempt is made to understand the etiology and 
differentiation into subgroups of GBS from an epidemiological perspective. The increase in 
incidence with age does not provide any clues because it is likely that not only the host 
susceptibility alters with age but also environmental factors and the incidence of preceding 
infections. With respect to the subgroups, the mild patient group, the MFS patients, the 
CMV related group and the Chinese paralytic syndrome are more frequently found at a 
younger age. In the MFS and in the CMV-related group, an association is described with 
respectively anti-GQ1 b antibodies and anti-GM2 antibodies. If future studies can show an 
association between age and the presence of anti-ganglioside antibodies, this not only 
explains the preference to occur at younger age for the two subgroups but also gives 
support to the suggested role of anti-ganglioside antibodies in the etiology of GBS. 
Because of the numerous differences between men and women it is difficult to explain the 
higher incidence of GBS in men. 
Overall, there is a striking similarity in the distribution of epidemiological characteristics as 
described in studies from all over the world. This suggests that the factors involved in the 
etiology of GBS must be present all over the world. Yet, it is also a fact that much know-
ledge including hypotheses on the mechanisms involved in the etiology of is GBS derived 
from exceptional and small clusters of patients showing distinctive epidemiological features. 
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All together, it is therefore recommended to apply the theory of sufficient cause and 
component causes on the present knowledge of GBS. Future studies should aim to construct 
a sufficient cause for every epidemiological phenomenon concerning GBS. Hereby, it is 
well possible that this leads to the identification of one, or more, necessary causes. 
Identification of necessary causes could be a valuable tool to clarity the pathogenesis of GBS. 
Clinical Aspects 
Studying characteristics of patients that developed a mild form of GBS, may generate 
clues about the mechanisms that induce this differentiation and thereby determine the 
course of the disease. In this thesis, two studies are described concerning mild patients. 
The first study was retrospectively conducted and part of a large epidemiological survey 
(paragraph 2.2). In this study we aimed to describe the group of mild patients and explore 
whether other differences than the level of severity existed, compared to the severely 
affected patient group. The results of that study encouraged us to perform the prospective 
study, which is described in paragraph 3.2. Some remarks must be made before evaluating 
and comparing the two studies on mild GBS patients. Table 1 shows that in both studies 
age less than 50 years was associated with a mild form of GBS. With respect to gender, 
the results were opposite and because of the numerous, and difficult to assess differences 
between men and women, this characteristic will not be considered here. From the 
retrospective as well as from the prospect'1ve study a preceding infection with Cjejuni or 
Mycoplasma pneumoniae does not seem to be an important factor in the differentiation 
into mild or severe GBS. In case of a preceding CMV infection, the outcome in the retro-
spective study differed from the outcome in the prospective study. In the latter study, 
serum samples were prospectively collected and tested. Therefore, we regard the data from 
this prospective study more representative and conclude that although not significant, an 
infection with CMV more frequently precedes GBS in the mildly affected group than in the 
severely affected group. The EBV results are more complicated. In the retrospective study, 
no difference was found between the two groups and the percentage with positive serology 
in the total group (mildly and severely patients) is comparable with earlier reports 20 In the 
prospective study, significantly more EBV infections preceded a mild course. However, the 
percentage with positive serology in the total group (mildly and severely patients) was 
much higher than in earlier reports 20 . One explanation for this finding could be the use of 
a new technique lor testing the antibody response to EBV in the serum of the GBS 
patients. Therefore we tested a control group of non-GBS patients, which was already 
tested with the former technique. Because the percentage of positive serology was compa-
rable in both tests, we conclude that the finding of a high percentage of preceded EBV 
infections among mild patients truly reflects the distribution of EBV infections in this group. 
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Only in the prospective study, we were able to assess the distribution of anti-ganglioside 
antibodies and found an absence of anti-GM1 and anti-GQ1 b antibodies in the mildly affec-
ted patients. Because of the low numbers, these findings must be interpreted with caution. It 
seems more appropriate to consider the difference in the total number of anti-ganglioside 
antibodies (12% in the mild group versus 45% in the severe group, p=0.01), rather than 
speculate about the absence or presence of a particular anti-ganglioside antibody. 
Table 1 Distribution of characteristics of mildly affected GBS patients in the 
* number of patients available 
** NA = not available 
All together it seems rational to centre the discussion around the major, and most convincing 
findings; the relation of mild forms with young age and the low percentage of anti-
ganglioside antibodies in general. 
Although age is frequently reported as prognostic factor for worse outcome 5;21 -23 , the 
studies described in this thesis are the first to show that age also influences the course 
and progression of the disease. Unfortunately, as mentioned earlier, age can not simply be 
regarded as a hostfactor. The influence of young age on the course of the disease can be a 
result of a high incidence rate at younger age of an agent that causes a mild course of the 
disease. From the results of the prospective study, it is attractive to mention EBV as res-
ponsible agent for determining a mild course. Unfortunately, no figures are available on the 
incidence rate of EBV in the Netherlands, so it is not known whether EBV infections occur 
more frequently at young age. The assessment of IR of EBV at young age, together with 
assessment of EBV serology in GBS patients in future studies might give support to the 
relation between a preceding EBV infection and the induction of a mild course of the disease. 
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C.jejuni infections in developed countries show a peak in incidence at age <1 year and at 
the age between 15 and 30 years 16. If a preceding infection would be the only. or an 
important factor in the differentiation into mild or severe form, one would, based on the 
relation between young age and a mild course, also expect a relation between preceding 
C.jejuni infection and a mild course. However, infections with C.jejuni can result in both mild 
and in severe forms of GBS. That C.jejuni can precede a severe course of GBS is shown in 
patients from Curayao, as described in paragraph 2.3, and is reported by others 19 ;24;25 . 
It is remarkable that most of these studies. including the Cura<;ao study. report on the 
frequent presence of anti-GM1 antibodies in the severe cases that were preceded with 
C.jejuni 19;25 . We found no anti-GM1 antibodies in patients with the mild form of GBS. This 
makes it attractive to attribute an important role to the presence of anti-GM1 antibodies, 
but also to anti-ganglioside antibodies in general, in the differentiation into a mild or severe 
form of GBS. Here again, the question rises whether there is a relation between age and 
anti-ganglioside antibody response, since this relation would further support an important 
role for anti-ganglioside antibody response in the course of the disease. One explanation 
could be that. with the progression of age the triggering of an anti-ganglioside antibody 
response increases, resulting in more damage to the nerves, causing a severe form of 
GBS. Although less likely. it can also be that the expression of gangliosides in the nervous 
system membrane changes during life and thereby increases the potential site of binding 
resulting in more damage. 
With the above-described relations, an attempt is made to explain the differentiation in the 
course of the disease between mild and severe forms of GBS. This was done with the results 
available from our studies. However, it is very likely that much more factors, probably not 
with equal strength, play a role in the differentiation into subgroups. This is probably a very 
complex process where the interplay of different preceding agents, in persons with different 
hostfactors, in different environments, results in the development of subgroups of GBS. 
Conclusion and direction for future research 
The studies on mild forms of GBS showed several differences in characteristics between 
patients with a mild course of GBS compared to patients with a severe course of the disease. 
Both the retrospective and the prospective study showed a relation between age and the 
differentiation ·1nto mild or severe GBS. Several differences were suggested explaining this 
relation with age, for example the increasing IR of the associated preceding infections with 
age. Interesting is the low percentage of patients with anti-ganglioside antibodies in the 
mild group. 
In order to further elucidate the complex mechanism by which the course of the disease 
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differentiates into a mild or a severe form, it is advisable to conduct further epidemiological 
research. First, the results of the epidemiological studies may generate clues that give 
direction to the work in other fields of research. For example, the studies described here 
show the importance of assessing the relation between age and anti-ganglioside antibody 
response. Before that, it seems appropriate to confirm the finding of the low anti-ganglioside 
antibody response in mild patients. Also confirmation of the distribution of preceding 
infections in the mild group is needed before definite relations can be considered. 
Second, the epidemiological theories of causation, for example the earlier mentioned theory 
of sufficient and component causes, can be used to structure and integrate information 
generated in different fields of research in GBS. 
Treatment 
In the introduction it was already stated that despite the availability of specific treatment 
like IVIg, morbidity and mortality is still considerable in GBS. Paragraph 4.2 describes a 
study in which the morbidity and mortality is compared between GBS patients admitted in 
small versus large centres. With the availability of IVIg treatment in small centres, the need 
to transfer patients to larger centres in order to receive treatment became obsolete. The 
results of this study showed that mortality and morbidity in GBS patients was independent 
of the type of healthcare facility. The exploration of other or additional therapeutic options 
is therefore needed. Furthermore, with the ongoing broadening of the spectrum of GBS, it 
seems appropriate to explore the need of therapy in subgroups. In this thesis we focussed 
on the mild form of GBS and on patients with MFS. By studying the course of the disease 
and the outcome, we explored the need for treatment studies in these two groups. We 
found that mildly affected patients report affected mobility at three and six months. 
Additionally, many patients reported severe fatigue and endurance intolerance. Because 
IVIg is the treatment of choice in the Netherlands, this seems the therapy of choice to study 
in mild forms of GBS. With respect to the prognosis, patients with mild forms of GBS must 
be made aware of the chance of incomplete recovery and the problem of fatigue. 
Although MFS is generally considered to be a benign variant of GBS, we showed in 
paragraph 3.3 that this GBS subgroup certainly not always recovers without residual 
signs. Furthermore in this group, again severe fatigue was reported as a major problem at 
three and six months after onset of the disease. Due to the low incidence of MFS, we 
concluded in paragraph 3.3 that conduction of an RCT in MFS does not seem feasible. 
Based on several arguments, the most important being the resemblance of the course of 
the disease with GBS, it was argued that treatment could be considered in especially the 
severely affected MFS patients, despite the lack of evidence provided by an RCT. Here again, 
one should be aware of the chance of incomplete recovery and fatigue when informing a 
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MFS about the prognosis of the disease. 
Paragraph 4.1 describes the results of a RCT on the additional effect of methylprednisolone 
on standard treatment with IVIg in patients with GBS. From 1994 to 2000, 225 patients 
were randomised to receive either IVIg and MP or IVIg and placebo. Based on the reported 
prognostic influence of age, patients were stratified >50 years and <:50 years of age. The 
primary endpoint was defined as the percentage of patients that improve one or more grades 
on the Hughes' disability scale. The ITT analysis showed that 56% of the patients in the 
placebo group reached the primary endpoint compared to 68% in the MP group (p=0.06, 
after adjustment for age p=0.05}. Including the relevant prognostic factors in a regression 
analysis the effect of MP treatment was convincing with a p-value 0.0015. The secondary 
endpoints almost all represented long-term conditions and did not show a difference bet-
ween the two groups, emphasising that the additional effect of MP in GBS mostly acts in 
the first months. The results of this RCT now offer an additional treatment option in 
patients with GBS. 
Conclusions and direction to future research 
Mildly affected GBS patients may still have considerable problems in mobility at three and 
six months after onset of the disease. The positive effect of PE in mildly affected patients 
has been described 26 . Since treatment with IVIg is preferable to PE, investigation of the 
effect of IVIg in patients with a mild form of GBS is ·Indicated. This could be evaluated in a 
setting where only mild patients are included, or these patients could be included in a 
RCT, where IVIg will at least be administered in a control group. 
Also in MFS not all patients recover without residual signs. Because of the low incidence 
rate of this subgroup and the resemblance with GBS, one might consider treating patients 
who are severely affected with IVIg. Both patients with the mild form of GBS and MFS 
reported fatigue as a major problem after physical recovery was completed. At this 
moment, different studies are conducted to investigate the benefit of therapy in fatigued 
patients who initially suffered from a severe form of GBS. If the results indicate that these 
treatments are effective, a study can be undertaken to study the effect in patients who 
suffered from a mild form of GBS or MFS. 
Our study describes the positive effect of the combination of IVIg and Mf' It was shown 
that this effect was mainly achieved during the first three months after onset Long term 
morbidity in GBS is still considerable. New treatment studies should therefore preferably 
focus on the reduction of long-term nerve damage due to GBS. 
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Summary 
Samenvatting 
Chapter 6 
6.1 Summary 
In this thesis studies are described concerning epidemiological and clinical aspects of the 
Guillain-Barre syndrome. GBS '1s an immune-mediated disease affecting the peripheral 
nerves resulting in a flaccid paralyis with or without involvement of the sensory system 
and cranial nerves. 
We studied the heterogeneity of GBS and thereby aimed to gain more insight in the patho-
physiological mechanism and clinical characterisation of the subgroups. 
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Chapter 2 describes the epidemiological studies in this thesis. First, in paragraph 2.1 an 
overview is given of the main epidemiological features on GBS described in the literature. 
Two unique epidemiological phenomena, the "swine-flu vaccin incident" and the "Chinese 
paralytic syndrome" are described in more detail. 
Paragraph 2.2. describes the epidemiological survey on GBS in the South-west 
Netherlands. With 4 76 patients included in this study, it is one of the largest studies in this 
field. All patients fulfilling the NINCDS-criteria for GBS were included from all hospitals in 
the South-west Netherlands from 1987 to 1996. This resulted in a crude incidence rate of 
1.18/100.000 inhabitants. The IR increased linearly with age and men were significantly 
more frequently affected than women. No seasonal preponderance was found, despite the 
fact that the occurrence of the most frequently associated preceding infections, shows a 
seasonal fluctuation. 
Paragraph 2.3 describes the study on the increasing number of GBS patients on the 
Carribean island Curayao. Here again, patients were included fulfilling the NINCDS-criteria 
for GBS. This resulted in an IR of 1.62 in the period 1987·1991 and an IR of 3.10 in the 
period 1992-1999, RR 5.22 (95%CI2.5-10.2, p~0.02). TheIR within the year showed a 
clear seasonal distribution. The patient group was characterised by a severe course with 
high mortality and a high percentage of pure motor forms. These findings, together with 
the high percentage of preceding gastro-enteritis reported and the high percentage of 
positive C.jejuni infections in the serum or stools of the patients, suggest a major role of 
C.jejuni in this increase in incidence of GBS in Curayao. 
In Chapter 3 studies are described on various clinical aspects of GBS. Paragraph 3.1 
and 3.2 concern studies on patients in which GBS runs a mild course, i.e. they remain 
able to walk unaided at maximum progression of the disease. Until now, most studies on 
GBS report on severely affected patients. Theories on the pathophysiological mechanism 
and results of treatment trials are therefore mainly based on severe patients while the 
retrospective study, described in paragraph 3.1 showed that 28% of the GBS patients is 
only mildly affected. Patients in this study derived from the survey as described in paragraph 
2.2. Because the distribution of the preceding clinical infections did not differ between the 
mild and severe patients in contrast to the preceded serological proven infections, we 
suggested that other pathogens could be responsible for the mild forms of GBS. To explore 
this, we performed a prospective study, which is described in paragraph 3.2. Here, almost 
all hospitals in the Netherlands reported their GBS patients in a two-year period. This 
resulted in 139 patients of which 14% was mildly affected. In the collected serum samp-
les, significantly more preceding infections with EBV were found in the mild patients. 
Furthermore, significantly less anti-ganglioside antibodies were found in the mild group 
and we concluded that this could be a factor involved in the determination of the course 
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of the severity of GBS. 
In paragraph 3.3 the treatment of the Miller Fisher patients was evaluated by studying the 
course of the disease and outcome in 12 patients included in the prospective study as 
described in paragraph 3.2. Because the course of the disease very much mimics that of 
GBS and a treatment trial would not be feasible because of the low incidence, we suggest 
that severely affected MFS patients can be treated with IVIg. 
Chapter 4 deals with randomised treatment trials in GBS. First. in paragraph 4.1 the 
results are described of a RCT on the effect of additional treatment with methylprednisolon 
(MP) on standard IVIg treatment. Two hundred twenty-five severely affected patients were 
included and it was shown that 56% of the placebo group and 68% of the MP-treated group 
reached the primary endpoint, P=0.06, P=0.05 after adjustment for age. After inclusion of the 
prognostic factors (age, number of days between onset of weakness and randomisation, 
MRC-score at entry and preceding CMV infection), the difference between the MP-treated 
and placebo group reached a p-value of 0.015. 
Paragraph 4.2 describes a study on the effect of publication of the former RCT on IVIg 
treatment in GBS in the Netherlands on the referral pattern of patients in the Netherlands. 
We hypothesised that the result of the positive treatment effect of IVIg in GBS patients, 
could be that more patients were treated in small centres because IVIg is available there. 
This could result in worse outcome for patients admitted in those small centers because 
GBS can give autonomic dysfunction and a need for mechanical ventilation, i.e. complica-
tions and events with which small centers have less experience. Our study showed indeed 
that fewer patients were referred from small to large centres after the introduction of lVI g. 
It also showed that this did not result in higher mortality or morbidity in small centers. We 
therefore concluded that high-risk patients were still transferred properly and thereby the 
introduction of IVIg has led to a more optimal use of specialised health-care facilities. 
Chapter 5 is the general discussion. In this chapter an attempt is made to translate the 
findings in this thesis to epidemiological concepts on etiology. Before that, some 
methodological aspects are discussed. Finally, besides general conclusions, guidelines 
and suggestions for future research are given. 
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6.2 Samenvatting 
Dit proefschrift beschrijft epidemio!ogische en klinische aspecten van het Guillain-Barre 
syndroom (GBS). GBS is een immuun-gemedieerde ziekte van de perifere zenuwen. 
Klinisch resu!teert dit in een slappe verlamming van de ledematen, al dan niet gepaard 
gaande met gevoelstoornissen en uitval van de hersenzenuwen. 
De nadruk in dit onderzoek ligt op de heterogeniteit van GBS. Hiermee werd beoogd meer 
inzicht te krijgen in het pathofysiologische mechanisms van deze ziekte. Tevens werd 
beoogd te komen tot een verdieping en uitbreiding van de karakterisatie van de diverse 
klinische subgroepen. 
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Hooldstuk 2 beschrijlt de epidemiologische studies van dit proelschrilt. Allereerst wordt 
in paragraaf 2.1 een overzicht gegeven van epidemiologische kenmerken van GBS zoals 
beschreven wordt in de literatuur. Twee unieke epidemiologische fenomenen worden 
nader belicht, te weten het incident rond het "swine-flu vaccine" en het zogenaamde 
"Chinese paralytic syndrome". 
Paragraaf 2.2. beschrijft een onderzoek naar het voorkomen van GBS in Zuidwest Nederland. 
Met het aantal van 476 patienten, is dit een van de grootste studies geworden op het gebied 
van de epidemiologie van GBS. Aile patienten die tussen 1987 en 1996 in ziekenhuizen in 
Zuidwest Nederland waren opgenomen en die voldeden aan de NINCDS-criteria voor 
GBS, werden ge'includeerd in de studie. Dit resulteerde in een incidentie van 1.18/100.000 
inwoners. De incidentie steeg lineair met de leeftijd en mannen waren significant vaker aan-
gedaan dan vrouwen. Er werd geen seizoensafhankelijkheid gevonden, ondanks het feit 
dat de bekende voorafgaande infecties bij GBS wei een seizoensvoorkeur kunnen hebben. 
Paragraaf 2.3 beschrijlt de studie naar het toenemende aantal GBS patienten op 
Curayao. In deze studie werden wederom pati8nten geincludeerd die voldeden aan de 
NINCDS-criteria voor GBS. Voor de periode 1987-1991 werd een incidentie van 
1.62/100.000 gevonden, voor de peri ode 1992·1999 een incidentie van 3.1 0. RR 5.22 
(95%CI 2.5·1 0.2, p=0.02). De incidentie over het jaar volgde een duidelijke seizoens-
gebondenheid. De patienten groep werd gekarakteriseerd door een ernstig beloop met 
een hoge mortaliteit en een hoog percentage van de pure motore vorm van GBS. Deze 
bevindingen, samen met het hoge percentage gevonden voorafgaande gastro-enteritis 
infecties en het hoge percentage gevonden positieve C.jejuni serologie, maken een rol 
voor C.jejuni in de stijging van de incidentie van GBS, zeer waarschijnlijk. 
In hoofdstuk 3 worden de klinische studies van dit proefschrift beschreven. Paragraaf 3.1 
en 3.2 gaan over de GBS pati8nten bij wie de ziekte mild verloopt, d.w.z. patienten die 
nog in staat zijn zelfstandig te !open op het dieptepunt van hun ziekte. Tot nu toe zijn de 
meeste studies betreffende GBS gebaseerd op ernstige pati6nten. Theorie8n over het 
pathofysiologische mechanisme en resultaten van therapeutische trials zijn dan ook voor-
namelijk gebaseerd op deze ernstige pati6nten terwijl in de retrospectieve studie, beschre-
ven in paragraaf 3.1, 28% van de GBS patienten slechts mild aangedaan is. De pati§nten 
uit deze studie zijn afkomstig van de survey beschreven paragraaf 2.2. Omdat de verde-
ling van de voorafgaande klinische infecties niet verschilde tussen de ernstige en milde 
pati8nten, in tegenstelling tot de serologisch bewezen voorafgaande infecties, is het 
mogelijk dater voor het ontstaan van milde GBS andere pathogenen verantwoordelijk zijn. 
Om dit te onderzoeken is een prospectieve studie verricht waarvan de resultaten beschreven 
staan in paragraal 3.2. In deze studie werden bijna aile GBS patienten in Nederland 
gedurende 2 jaar ge·lncludeerd. Dit resulteerde in 139 GBS pati8nten van wie 14% mild 
pagina 131 
Chapter 6 
aangedaan was. In de verzamelde serum monsters werden significant meer voorafgaande 
infecties gevonden met het EBV virus in milde pat lenten. Verder werden er significant minder 
anti-ganglioside antilichamen gevonden in de milde groep. Wij concludeerden dan oak dat 
dit een factor zou kunnen zijn die betrokken is bij het bepalen van de ernst van de ziekte. 
In paragraaf 3.3 wordt de behandeling van Miller Fisher patienten geevalueerd aan de hand 
van de bestudering van het beloop van de ziekte en herstel in 12 pati8nten die includeerd 
werden in de prospectieve studie beschreven in paragraaf 3.2. Daar het beloop van de 
ziekte vee! overeenkomsten vertoonde met GBS en een therapeutische trial niet haalbaar 
geacht wordt vanwege de lage incidentie, werd er geconcludeerd dat ernstige MFS pati-
enten behandeld zouden kunnen worden met IVIg. 
Hoofdstuk 4 beschrijft studies die betrekking hebben op therapeutische trials en GBS. 
Allereerst worden in paragraaf 4.1 de resultaten beschreven van de gerandomiseerde 
dubbelblinde trial naar het additionele effect van methylprednisolon naast standaard IVIg 
therapie. Tweehonderdvijfentwintig ernstige patienten werden geincludeerde. Zesenvijftig 
procent in de placebo groep en 68% in de MP-groep behaalden het primaire eindpunt, 
p=0.06, p=0.05 na correctie voor leeftijd. Na inclusie van de prognostische factoren in de 
analyse (leeftijd, aantal dagen tussen begin van de zwakte en randomisatie, MRC-score 
ten tijde van inclusie en een voorafgaande infectie met het CMV virus), bereikte het ver-
schil tussen de MP groep en de placebo groep een p waarde van 0.015. 
Paragraaf 4.2 beschrijft een studie naar het effect van publicatie van een eerdere therapeu-
tische trial in GBS op het verwijzingspatroon van de patienten. Doordat deze trial aantoonde 
dat !VIg minstens zo effectief was als plasmaferese, was het nu mogelijk patiSnten in kleine 
centra te behandelen daar IVIg in deze centra beschikbaar is in tegenstelling tot plasmafe-
rese. Dit zou kunnen leiden tot een slechter herstel in deze patiSnten omdat GBS kan 
resulteren in autonome disfunctie en behoefte aan mechanische beademing. Seide zijn 
complicaties waar kleinere centra weinig ervaring mee hebben. In deze studie werd aan-
getoond dater inderdaad minder patienten verwezen worden van kleine naar grate centra 
na de introductie van IVIg als therapeuticum. Echter dit resulteerde niet in een stijging van 
de mortaliteit en morbiditeit in kleine centra. Het b!eek dat pati8nten met een hoog risico 
op complicaties nag steeds adequaat worden doorverwezen naar grotere centra. Er werd 
geconcludeerd dat de introductie van IVIg in Nederland heeft geleid tot een meer optimaal 
gebruik van zorginstellingen. 
Hoofdstuk 5 is de algemene discussie. Hierin is getracht de bevindingen in dit proefschrift 
te vertalen naar epidemiologische concepten wat betreft het ontstaan van het Guillain-
Barn§ syndroom. Allereerst worden enkele methodologische aspecten besproken. Verder 
worden suggesties gedaan voor eventueel toekomstig onderzoek. 
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AIDP 
AMAN 
AM SAN 
CDC 
CIDP 
C.jejuni 
CMV 
CSF 
EBV 
EMG 
F-score 
GBS 
lCD 
IR 
IVIg 
PE 
MFS 
MP 
Mpneu 
MRC 
NINCDS 
PCB 
RCT 
acute inflammatory demyelinating polyneuropathy 
acute motor axonal neuropathy 
acute motor-sensory axonal neuropathy 
centers for disease control and prevention 
chronic inflammatory demyelinating polyneuropathy 
Campylobacter jejuni 
Cytomegalovirus 
cerebrospinal flu'1d 
Epstein-Barr virus 
electromyogram 
functional grading score 
Guil!ain-Barre syndrome 
international classification of disease 
incidence rate 
intravenous immunoglobulin 
plasmapheresis 
Miller Fisher syndrome 
methylprednisolone 
Mycoplasma pneumoniae 
medical research council 
National Institute of Neurological Disorders and Stroke 
pharyngo-cervico-brachial 
randomised controlled trial 
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